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Prostate cancer is one of the most common malignancies affecting blacks worldwide.  Blacks 
have a higher incidence and prevalence of prostate cancer than Caucasians.  Treatment for 
prostate cancer usually involves androgen deprivation therapy.  Even though androgen 
deprivation therapy has a high efficacy there are many deleterious side effects such as increase in 
body fat. Consequently, we investigated the association between androgen deprivation therapy 
for prostate cancer and the rate of change of percent total body fat in a cohort of Afro-
Tobagonian men. Case-control analysis of 1691 men in our study indicated that, men with 
prostate cancer exposed to ADT had higher increases in percent total body fat over time 
compared to unexposed men with prostate cancer. 
Likewise, obesity and hypertension disproportionately affects individuals of African 
descent.  These complex diseases are multi-factorial in origin and are typically controlled by 
many genes.  ADRB2 and AR CAG repeat lengths have been widely studied in the literature and 
these genotypes were available for study in the Tobago Prostate Study; consequently, we 
investigated the association between ADRB2, body composition and blood pressure.  We also 
investigated the association between AR CAG repeats and body composition.  
Cross-sectional analysis of 2,584 men in our cohort indicated that, men with shorter AR 
CAG repeats had higher body fat measurements (DEXA).  We found that the direction of the 
association was opposite what we had anticipated, of men with longer AR CAG repeats having 
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higher body fat measurements.  1,965 men were investigated cross-sectionally to determine the 
association between ADRB2, body composition and blood pressure.  We found no association 
between ADRB2, DEXA measures of body fat and blood pressure. 
In our cohort of Afro-Tobagonian men AR CAG repeats and ADRB2 did not show an 
association with our outcome of interest.  Even though we had non-significant findings, other 
genes should be evaluated to assess if an association exists with body composition and blood 
pressure in Tobago population.  These studies are of public health relevance or importance 
because they contribute epidemiologic information to the body of scientific information available 
especially regarding Tobago men.   
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1.0  INTRODUCTION 
Prostate cancer is considered one of the most common carcinomas and is the leading cause of 
cancer death in American men.  African American men have the greatest risk for the disease and 
there is some suggestion that there might be some ethnic variation in prostate cancer risk. 1, 2  
Androgen deprivation therapy with GnRH is the most common treatment for metastatic prostate 
cancer.  In addition, androgens are important determinants of body composition in men.  Serum 
Testosterone concentrations have been shown to correlate positively with muscle mass and 
negatively with fat mass. 1GnRH agonist treatment in men has been shown to reduce bone 
mineral density, which is an important determinant of fracture risk.  Furthermore, the changes in 
body composition may contribute to the adverse effects of physical function and potentially their 
quality of life. 1 
Lean mass, fat mass and body weight have been shown to be associated with high bone 
mineral density (BMD).  Several studies indicate that a decline in lean body mass, or body 
weight is associated with declines in BMD.3, 4  It is hypothesized that sex steroid hormone levels 
(testosterone and estradiol) contribute to low BMD and bone loss in older men  and vary 
according to ethnicities.5 Variations in BMD are mostly genetic but other factors such as 
environment, nutrition and physical activity can play an important role6.  There is still 
uncertainty regarding the independent risk factors for BMD in men and women.  Many of the 
studies related to BMD have been conducted in women because of bone loss following 
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menopause17 Despite lower osteoporotic risk in African Americans the number of individuals 
afflicted by this disease is expected to increase exponentially in the next few years.  
High blood pressure has been shown to be relatively common in the West Indies 8.  
Patrick et al.9 showed that Tobagonian’s have higher blood pressure levels, body bulk and 
obesity compared to mixed African populations of Jamaica, Guyana, and the European 
Caucasian populations of rural Wales.9In Tobago (2006), hypertension/high blood pressure and 
its co-morbidies account for approximately 35% of all yearly visits to health care facilities and is 
considered a significant contributor to morbidity and mortality.10 
The literature is replete with evidence that genes influence obesity,  and body fat 
distribution4.  The development of many metabolic diseases such as CVD, prostate cancer, high 
blood pressure and T2DM is influenced by lifestyle and also genes.  Obesity and insulin 
resistance are key risk factors for these diseases.  Metabolic diseases such as T2DM are 
associated with aberrations in the lipid metabolism that typically cause fat accumulation in the 
liver and muscle.11  Even though many of these studies have indicated a genetic basis for these 
diseases, many of the variations in these diseases are due to genes that are yet unidentified.  
Furthermore there is little information in the literature regarding genetic factors influencing body 
fat, and body fat distribution in populations of African decent. 
Tobago would serve as an important population to investigate the impact genetics has on 
various diseases. Since Tobago is comprised mainly of West African ancestry with miniscule 
European and Native American admixture, the Tobago population may carry a higher prevalence 
of high risk alleles of African origin compared to more admixed populations.12  The objective of 
this study is to determine the association between CAG AR repeat length polymorphism(Xq11-
12), androgen deprivation therapy (ADT), #2-adrenergic receptor polymorphism (5q33.1) and 
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high blood pressure, body composition, and low bone mineral density in a subset of Tobagonian 
men in the Tobago Bone Follow-up Study.  
1.1 SPECIFIC AIMS 
!"!"! Project 1:#$%adrenergic receptor (ADRB2) genotype, body composition, and 
blood pressure in African-Caribbean men from Tobago&
The Tobago Prostate Cancer Study determinedADRB2 genotype (single nucleotide 
polymorphism (SNP) rs1042714), performed dual energy X-ray absorptiometry (DEXA), and 
measured height, weight, waist circumference, and blood pressure in N=1965 Afro-Caribbean 
men from Tobago. Research questions include 1) the association between ADRB2 rs1042714 
genotype and obesity and 2) the association betweenADRB2 rs1042714 genotype and blood 
pressure. Research hypotheses include, 
1. Men with one or two copies of a variant ADRB2 rs1042714 allele have more body fat, 
expressed as DEXA measured total body fat as a percentage of total body mass, and 
2. Men with one or two copies of a variant ADRB2 rs1042714 allele have higher blood 
pressure. 
1.1.2 Project 2: Androgen receptor (AR) genotype and body composition in 
African-Caribbean men from Tobago 
The Tobago Prostate Cancer Study determinedAR genotype (CAG trinucelotide repeat 
polymorphism length) and performed dual energy X-ray absorptiometry in N=2,584 Afro-
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Caribbean men from Tobago. Research questions include 1) the association between AR 
genotype (expressed as the number of CAG repeats) and obesity.  Research hypotheses include, 
 
1. Men with longer AR alleles (more CAG repeats) have more body fat, expressed as DEXA 
measured total body fat as a percentage of total body mass, and 
1.1.3 Project 3: To examine the association between androgen deprivation therapy 
(ADT) for prostate cancer and body composition 
The Tobago Prostate Cancer Study performed dual energy X-ray absorptiometry in greater than 
equal to 40 year-old Afro-Caribbean men from Tobago, before and after androgen deprivation 
therapy (ADT) for prostate cancer. Research questions include 1) the association between 
androgen deprivation therapyandtemporal change in body composition. Research hypotheses 
include, 
1. ADT-treated prostate cancer men will experience a gain in DEXA body fat mass 
(expressed as a percentage of DEXA total body mass) more rapidly than ADT-untreated 
prostate cancer men and men without prostate cancer  
1.2 BACKGROUND 
1.2.1 Epidemiology 
Prostate cancer is the second leading cause of death in American men.  It is estimated 186, 320 
men will be diagnosed with prostate cancer and 28, 8660 men will die of cancer of the prostate in 
2008.  The age adjusted incidence rate is 163.0 per 100, 000 per year and the age adjusted death 
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rate is 26.7 per 100, 000 men per year. This data is based on diagnosedcases /patients who died 
in 2001-2005 from 17 SEER locations. 13 
In men with prostate cancer androgen deprivation therapy (ADT) is being widely used in 
patients with prostate carcinoma.  Even though, ADT therapy is effective in controlling prostate 
cancer, hypogonadism as a result of ADT treatment is associated with many adverse effects for 
instance: impotence, hot flashes, cardiovascular morbidity, and osteoporosis 14.  Osteoporosis is 
no longer a disease that only affects women. There is growing concern, regarding men with 
osteoporosis.  In the United States there is approximately 1.5 million men >65 with osteoporosis 
and another 3.5 million men with osteopenia (low bone density), potentially increasing their risk 
of fractures. 15 
In the literature there is limited data showing that men with prostate cancer could have 
preexisting low BMD 16-19 and also showing that ADT causes additional decreases in BMD in 
men. 17, 18, 20, 21 In addition to the loss in BMD another problem with ADT is the change in body 
composition. Changes in body composition are adverse side effects of androgen deprivation. 19 
Further more, studies show that body composition is related to other diseases such as 
diabetes and hypertension22, 23an increase in body mass and decreases in muscle mass is typically 
a result of reduced androgen levels in men.24-27  It is hypothesized that reduced muscle mass will 
lead to decreased muscle strength, which would increase the risk of bone fractures in men.  Even 
though, the literature is replete with studies emphasizing the effects of hypogonadism on body 
composition 28 research on body composition among men with prostate cancer after receiving 
ADT therapy is rarely discussed.14 
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1.2.2 Anatomy of the Prostate 
The prostate gland is an exocrine organ that measures 25cc and is located in the pelvis 
between the bladder and the urinary sphincter, anterior to the rectum and below the pubis.  The 
prostate is comprised of lobular tubuloalveolar glands that secrete fluids into the prostatic 
urethra.  This fluid is comprised of seminal emissions that are rich in prostate-specific-antigen 
(PSA).  Because of the location of the prostate the treatment of prostate cancer can have 
significant effects on urinary, sexual and bowel function.29 
Most cancers of the prostate seem to develop near the capsule of the prostate in the 
peripheral zone.  Prostate cancer is considered a multifocal disease in which tumors are present 
throughout the gland.  The spread of prostate cancer can occur through defects in the capsule in 
which the neurovascular structures and the ejaculatory ducts enter the gland or possibly in the 
region of the bladder neck.  The cancer can also progress to the seminal vesicles, bladder neck or 
the levator muscles. Systemic spread of the disease can also occur through the lymphatics to the 
external iliac, hypogastric, obturator, and presacral nodes.  Prostate cancer has also been shown 
to have a predilection towards bone because of the bidirectional interaction between tumor cells 
and the surrounding stroma.29 
A number of hereditary and environmental risk factors have been hypothesized in the risk 
of prostate cancer.  These risk factors include, age race and family history which are the 
generally accepted risk factors in the development of prostate cancer.30 
1.2.3 Pathogenesis of the Prostate 
Prostate cancer is a heterogeneous disease that is caused by a series of genetic events in the 
prostate.  These genetic events along with environmental risk factors can promote the 
development of cancer of the prostate.31, 32 
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1.2.3.1 Risk factors 
Increasing Age 
Aside from being of male sex age is considered one of the most important risk factors for 
prostate cancer. Prostate cancer is an age-related adult malignancy. Prostate cancer rarely occurs 
before the age of 40 years but the incidence seems to rapidly increase there after.32  Bunker et 
al.,33 found that prostate cancer rates increased with increasing age in the Tobago population 
with the highest rates being detected between the ages of 60-69 years (18%) and 70-79 years 
(28%). 
Race and ethnicity 
Men of African descent have the highest prostate cancer morbidity and compared to other racial 
or ethnic groups.34, 35  Even though the overall morbidity and mortality from prostate cancer has 
been declining in whites since 1991 possibly due to improvements in diagnosis techniques, 
screening, surgical and radiologic treatments the rates in African American men are still high; 
approximately 2.4 times higher than in White men.34 Furthermore, within the last couple of 
years, prostate cancer has emerged as the most common cancer in African American men and is 
considered the second most common cause of cancer related deaths in the western world.36, 37 
Black men of African descent have high incidence of prostate cancer and men residing in 
some regions of Caribbean have rates similar to that of US black men.  Glover et al.38 provided 
some significant data, as prior to his study African American men in the United States were 
considered to have the highest rates of prostate cancer.  The international agency for research in 
cancer (IARC) in the GlOBOCAN software and database had estimated the incidence rate of 
prostate cancer in Jamaica to be 42.4 per 100,000 39. However, Glovers’ retrospective study of 
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1,000 prostate cancer cases in Kingston between the years of 1989-1994 (by evaluating Jamaican 
Cancer Registry, hospital, and clinic records) showed that the true prostate cancer incidence in 
Kingston, Jamaica was 304 per 100,000 which is significantly higher than US blacks and is 
considered to be the highest incidence in the world.  The findings from Glover et al.38 of high 
rates of prostate cancer was further supported by Brooks and Wolf 40 who found that prostate 
cancer is the most prevalent cancer in Jamaican men in St. Andrew and Kingston between the 
years of 1958-1987.  Moreover, in 2001 Hanchard et al.41 reported that prostate cancer is the 
main site of cancer in Kingston and St. Andrew based on 1,941 malignant neoplasms.  
Bunker et al.33, 35, 42 reported on information in three studies relevant to Trinidad and 
Tobago.  In that population based prostate cancer study of men 40-79 years screening for 
prostate cancer was determined via serum prostate-specific antigen (PSA) and digital rectal exam 
(DRE).  This study determined prostate cancer prevalence to be 11% i.e. (277cases out of 2,583 
men) 42.These findings were further supported by an earlier study by Bunker et al.,33 in the same 
population.  In 2002 another study by Bunker et al.35 compared prostate cancer prevalence in 
men of West African decent residing in Tobago and Asian-Indian men in Trinidad between the 
ages of 50-64 years. Afro-Tobagonian men had higher prevalence of prostate cancer (8.3%) 
compared to Asian-Indian men (2.3%).  This difference observed was also true for all age 
categories: 50-54; 55-69; and 60-64 years. 
In a study by Phillips et al.43 that evaluated cancer incidence and mortality in the 
Caribbean showed that Puerto Rican men had a high incidence rate of prostate cancer 100.1 per 
100,000 and men in Barbados had similar rates of 99.7 per 100, 000.  Cuban men had the lowest 
rate 28.2 per 100, 000, however, Barbados men had the highest mortality rate 68.1 per 100,000 in 
the Caribbean and Haitian men had the lowest mortality rate of 20.0 per 100, 000. 
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Migrant studies also show that people of African descent have high rates of prostate 
cancer.  Black men residing in the United Kingdom (UK) are considered an interesting 
population to examine because that population is mostly comprised of Afro-Caribbean and West 
African men 34.  Typically immigrants bring with them patterns of disease that characterize their 
country of origin.  However, over time immigrant groups or their progeny usually adopt a pattern 
similar to that of the host country43.  Consequently, the UK represents a unique microcosm of 
people of Afro-Caribbean and West-African populations.  The Prostate Cancer in Ethnic 
Subgroups (Process) Study evaluated new prostate cancer diagnosis between January 1, 1999 
and December 31, 2000 in the regions of: London Boroughs of Tower Hamlets; Hackney; New-
ham and the city of London.  These parishes are comprised of 600,000 individuals with 
ethnicities of: white (British, Irish, and other white), black (black Caribbean, black African and 
other black, white and black African mix, white and black Caribbean mix), Asian (Indian, 
Pakistani, Bangladeshi, other Asian, white and Asian mix). This study reported 248 European, 91 
African-Caribbean, and 20 south Asian prostate cancer cases.44 
In addition, in a retrospective follow-up study in Process on prostate cancer incidences in 
North Bristol, South West London, South East London, and North East London from 1997-2001 
reported 2,140 cases: 61.4% white, 20% Black Caribbean, 4.8% Black African, and 7% un-
coded ethnicity.2 
Family History 
The incidence of prostate cancer is greater/higher in men with a family history of a relative with 
prostate cancer.  This risk increases with the number of affected family members.  First-degree 
relatives of men with prostate cancer have a two-threefold increased risk of developing prostate 
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cancer.  Men with two or more relatives with prostate cancer have a fivefold increased risk of 
developing this disease.45 
Studies have shown that familial prostate cancer constitutes approximately 5-10% of all 
prostate cancers and approximately 50% of all prostate cancers in men younger than 55 years of 
age.46 
Diet and lifestyle 
Studies have reported that dietary intakes of high saturated fats, red meats, high total 
consumption, low fruits, low vegetables, low tomato products, low fish and low soy products 
increase the risk of prostate cancer. Vitamin D, calcium, lycopene, zinc, omega-3 fatty and 
alpha-linolic fatty acids, selenium, vitamin E, statins, and non-steroidal anti-inflammatory 
medications have also been shown to affect risk.  In addition, certain anthropomorphics and 
activity have been shown to be linked to prostate cancer.29 
Likewise, higher circulating insulin like growth factor -1(IGF-1) can affect risk. It has 
also been shown that ejaculatory frequency maybe protective but the number of sexual partners 
can affect increase one’s risk.  The association between obesity and prostate cancer is somewhat 
controversial however obesity is associated with higher grade prostate cancer which could be 
caused by lowered testosterone levels.29 
1.2.4 Clinical risk factors for prostate cancer 
Most prostate cancer cases are considered adenoma carcinomas that are derived from glandular 
epithelial cells.  Furthermore, autopsies have shown that middle age individuals have a 
prevalence of malignant precursor prostatic intraepithelial neoplasia (PIN) and invasive 
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cancers.31 When a biopsy shows PIN but not actual cancer further biopsy is typically 
warranted.32 
Symptoms 
The general symptoms of prostate cancer are urinary frequency, nocturia, and urgency, which are 
typically caused by the obstruction of the Urethra.  However, in some individuals symptoms may 
come from painful skeletal metastases or anemia caused by bone marrow replacement.31 
Screening and detection 
Various studies have shown that a PSA level >4ng/mL increases the likelihood that prostate 
cancer will be detected at a prostate biopsy. Programs focused on early detection prostate cancer 
have reported that approximately 70% of cancer cases can be detected by using a PSA cut-off of 
4ng/mL.47 
PSA test can provide diagnostic lead-time of 5-10 years.  Approximately 80% of PSA 
cancers are biologically significant based on tumor volume and also Gleason grade.  The use of 
PSA, results in earlier detection and diagnosis of organ confined disease.29 Furthermore, experts 
assert that the use of PSA and DRE has resulted in the downward spiral of cancer mortality in the 
last few decades.  The use of PSA screening method has resulted in increased number of 
diagnosed cases and the identification of cancer in the early stages.29 
Currently, the American Cancer Society recommends annual DRE and PSA test for men 
50 years and older who have a life expectancy of over 10 years.  For men who are considered 
high-risk i.e. African American men and men with a family history of prostate cancer screening 
should commence at 40 years of age.32, 48 
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Digital rectal exam (DRE) 
Typically physical findings are limited to the rectal examination.  Attention is usually paid to 
areas of induration and also to determine if there is extension laterally to the pelvic sidewall, 
superiorly to the seminal vesicles and inferiorly at the apex.  If it is determined that there is 
urinary obstruction, the bladder might be palpable.  This examination is subjective and may not 
correlate cancer volume or extent of disease.  Non-the-less, DRE results are an important facet of 
the algorithms that are used to determine if cancer is confined to the prostate gland or if it has 
spread to other regional areas.49-52 
Gleason score 
The Gleason score is used to microscopically evaluate prostate tissue and provide careful 
histologic grading.  This is considered one of the most important factors in understanding clinical 
outcomes and prognosis of this heterogeneous disease.29 
Gleason grading evaluates the architectural details of cancer cells under a low-to –
medium magnification.  There are five patterns of growth from well to poorly differentiated.29 
For instance, pattern 1 is the most differentiated with discrete glandular architecture where as 
pattern 5 is the most undifferentiated, showing loss of glandular architecture.  Consequently, the 
final Gleason score is the sum of the grades of the most common plus the second most common 
growth patterns.  The Gleason score can range from 2(1+1) to 10(5+5).29 The Gleason score 
correlates to clinical prognosis and is used to stratify individuals. 
1.2.5 Androgens 
Testicular androgens influence the development of the normal prostate and also play a key role 
in neoplasia.  Testosterone is the main circulating androgen in the blood.  Males who reach 
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castration levels of testosterone before puberty (eunuchs) do not seem to develop benign 
prostatic hypertrophy or prostate cancer 53. 
Adrenal androgens androstenedione,dehydroepiandrosterone, and dehydroepiandro-
sterone sulfate can also be converted to testosterone and DHT but they provide a small 
proportion of circulating androgens hence they do not support the growth and development of the 
normal prostate.  They however, could play an important role in advanced prostate cancer as a 
residual source of testosterone and DHT and by binding directly to mutant ARs.  DHT is 
considered an extremely potent intracellular mediator both in the internal and the external 
genitalia 59. 
1.2.5.1 Racial differences in sex steroid hormones 
Studies have shown that African American men have higher mean circulating testosterone levels 
and other androgens compared to European men of comparable age.  This difference in 
testosterone levels is higher during young adulthood (10-20%) 54, 55 than in mid–adulthood (30%) 
55.  There is also greater age decline in testosterone levels in African American men compared to 
European men until the age of 40 years (6.7%>than white men age 31-34years; 3.7% by age 35-
39; and 0.5% by age 40-50 years) 55.  Epidemiologic studies suggest that testosterone levels 
decline as part of the natural aging process in men.  In addition, to this decline in testosterone 
there is an age related increase in sex hormone binding globulin (SHBG) which binds to 
approximately 44% of testosterone. The non-SHBG-bound testosterone fraction seems to 
decrease with increasing age.  Suggested reasons for this decline is, decreased Leydig cell and 
secretory functions which might contribute to declining serum testosterone levels 56, 57.  Harman 
et al.56 suggest that modifiable lifestyle factors that are associated with aging could play a key 
role in the decline in testosterone levels. 
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In the CARDIA study, 483 African men and 695 European men aged 24-34 years at 
baseline were evaluated.  In this study African American men were found to have 3% higher 
mean serum testosterone levels compared to European men even after adjusting for age, body 
mass index at baseline, and change in BMI after three hormone assessment in 8 years 58.  The 
decline in testosterone with age was similar between African American and European men.  
Following the adjustment of baseline waist circumference and change in waist circumference 
racial difference in testosterone levels were eliminated.  It should also be noted that in this study 
the African American men had smaller waist circumference and they had a greater increase in 
waist circumference over time compared to European men.  In addition there were no racial 
differences in sex hormone binding globulin and free testosterone.  Observations made from the 
CARDIA study suggested that observed racial variability in hormone levels might not be the 
result of inherent differences across racial groups but rather differences in certain factors that 
contribute to hormone levels such as: BMI, waist circumference which are inversely correlated 
with testosterone.  On the other hand, racial differences in body habits could be caused by 
inherent differences in systemic hormone 59. 
Racial differences in androgen variability in utero showed that mean serum testosterone 
levels were 50% higher in African American mothers in the first trimester compared to age, 
week of gestation matched European women 60.  Another study observed higher maternal 
testosterone levels at delivery in African American women even after adjustments for known 
predictors of maternal testosterone levels.  On the other hand, there were no observed differences 
in cord blood testosterone levels (African American 19.9, European 20.6 ng/dl).61. 
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1.2.5.2 Definition of maleness and androgenecity 
The variations between genders are moderated by sex hormones.  This process typically starts in 
the uterus. A complete insensitivity to testosterone leads to a female phenotype expression. 
Maleness is described as, “the phenotypical correlation of androgen effects in humans” 62.  
Furthermore, maleness is denoted as, the degree of androgenicity.  A male phenotype that has not 
been exposed to adequate androgen will vary according to the time of exposure but the major 
hallmarks will be during foetal development and also puberty.  Moreover, because AR can be 
found in almost every tissue androgenicity is typically exerted everywhere.  The areas that are 
most affected will be the places with an abundance of androgen receptors such as:  prostate, 
testis, bones, larynx, brain, haematopoetic cells and certain types of hair follicles.62 
Persons affected by low androgen levels typically present with small prostates, low 
spematogenesis, low bone density, a high pitched voice, anemia, feminized pattern of secondary 
hair growth, decreased libido, depression, and poor spatial cognition abilities.  The effect of 
androgen has also been detected in lipid and glucose metabolism, even in fat cell physiology.63 
Testosterone (T) and its metabolite dihydrotestosterone (DHT) cause gene expression 
through the androgen receptor (AR).  Typically T levels within normal range will saturate 
existing ARs and their androgenic effects will reach plateau levels depending on the type of 
tissue 64, 65.  Consequently, it is reasonable to think that within a particular range of saturation, 
genetically determined differences in androgen receptor activity would be observed, where as in 
the condition of hypogonadism, androgenicity is dependent on the levels of T and DHT.62 
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1.2.5.3 Androgen metabolism in the prostate 
The pathway for androgen metabolism involves the two steroid hormones testosterone and 
dihydrotestosterone, the androgen receptor and important genes in the nucleus that are regulated 
by androgens 53.  
In males testosterone is primarily synthesized by the testes and to a small extent by the 
adrenal glands.  Approximately 45% of circulating testosterone binds to the sex hormone binding 
globulin (SHBG), 50% binds to albumin and <4% is unbound free testosterone 66.  Testosterone 
diffuses into the prostate from blood and then binds directly to the AR 53. Testosterone in the 
prostate is converted irreversibly to 5'%dihydrotestosterone by the enzyme 5'-reductase type II 
which is encoded by the SRD5A2 gene66.  Even though testosterone and 5'%dihydrotestosterone 
can bind to the androgen receptor; the androgen receptor has a higher affinity for the 
5'%dihydrotestosterone than for the testosterone.  In addition, the androgen receptor is more 
transcriptionally active when it is bound to the 5'%dihydrotestosterone. The 
5'%dihydrotestosterone –androgen receptor–transcription factor is regulated by translocation to 
the cell nucleus and binding of androgen receptor co-regulators, co-activators, and co-repressors.  
Furthermore, the 5'%dihydrotestosterone coregulator complex translocates to the cell nucleus, in 
which once there it activates the transcription of genes with the help of other hormone responsive 
elements67.  The amount of 5'%dihydrotestosterone in the prostate is determined by: testosterone 
metabolism, metabolism of androstenedione via 5'%androstanedione and 
5'%dihydrotestosterone (DHT) inactivation by its reduction to 3'&or 3#&- androstanediol which 
is a reversible process. The metabolites of 5'%dihydrotestosterone can also be conjugated into 
3'&or 3#-androstanediol glucuronide which is also an irreversible process 67.  3#-androstanediol 
glucuronide is considered a terminal metabolite of testosterone and is used as a surrogate marker 
  17 
of tissue androgen levels.  3#-androstanediol glucuronide reflect the activities of 5'-reductase 
types I and II.  Type I is typically expressed in extraprostatic tissue like the skin and type II is 
expressed in the prostate 68.  Serum concentrations, of 3'-androstanediol glucuronide correlates 
with 5'-reductase activity in the genital skin.Finasteride a 5'-reductase type II inhibitor show 
that DHT and 3'-androstanediolglucuronide decrease in men who were treated 69. 
1.2.5.4 Serum testosterone, obesity, age, and tumor grade 
There are many unresolved issues with serum androgen.  It is well established that serum 
androgen decreases with increasing age and increasing age is a major risk factor for prostate 
cancer along with race and family history 69.  In the literature there is evidence that high levels of 
serum testosterone is associated low grade prostate tumors but a decreased risk for high grade 
prostate tumors 70, 71. There is no evidence showing that total testosterone is associated with a 
decreased risk of high grade tumors but there is a possible association between free testosterone 
(unbound testosterone) and an increased risk for low grade tumors 70.   
The deleterious effect of obesity also complicates the relationship between androgens and 
prostatic tumors.  Hsing et al. 70 observed that obese men have a decreased risk of low grade and 
an increased risk for high-grade tumors, which is consistent with other findings that these men 
also have low serum testosterone levels 72, 73.  This evidence further corroborates the findings 
that high serum testosterone concentration is associated with increased risk of low-grade prostate 
cancer and a reduced risk of high-grade prostate cancer.  Obesity is associated with increased 
inflammatory markers, which are associated with a risk of prostate cancer 74.  However, these 
observations may be modified by other additional modifiers and needs further evaluation.  
  18 
1.2.5.5 Androgen deprivation 
The concept that androgen deprivation can affect body composition was first proposed by 
Charles Edouard Brown-Sequard in 1889 75 he has been credited by many as the founder of 
endocrinology because he was the first person to suggest the existence of substances that are 
secreted by a particular organ but affects others 76. 
Male hormones called androgens (testosterone and dihydrotestosterone) is responsible for 
determining male secondary sex characteristics and is also responsible for stimulating prostate 
cell growth.  Once prostate cells are deprived of androgens both healthy and cancerous they no 
longer grow and hence eventually die 77. 
Androgen deprivation therapy also denoted androgen suppression therapy and hormone 
therapy uses drugs or surgery to suppress or block male hormones (testosterone and 
dihydrotestosterone) that cause prostate cell growth.  Testosterone is an androgen and androgens 
are produced by the testis and small amounts are also produced by the adrenal glands located on 
top of the kidneys.  Androgen deprivation therapy blocks the production and the effects of 
androgen on the body.  Androgen deprivation therapy is not considered a cure for prostate cancer 
but it can control symptoms and also disease progression in individuals.  Androgen deprivation 
therapy is used to treat metastatic cancer and localized prostate cancer depending on PSA levels 
77. 
In the literature there has been some debate as to when to commence androgen 
deprivation therapy.  According to a report in 2007 by American Cancer Society of Clinical 
Oncology (ASCO) patients with recurrent, progressive or advanced prostate cancer should delay 
treatment until patients begin to experience symptoms.  However, if therapy is deferred patients 
should have regular visits with their physicians (every 3-6 months) to monitor their condition.  
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ASCO also recommends bilateral orchiectomy, or injections with luteinizing hormone-releasing 
hormone as initial androgen deprivation treatments.78ADT treatment is considered palliative care 
and rarely curative.  In the literature there is evidence to suggest that early treatment results in 
better long-term prognoses for prostate cancer.29, 32 
1.2.6 Treatment of prostate cancer 
1.2.6.1 Orchiectomy 
Orchiectomy is the surgical removal of the testicles.  This method is considered the most 
effective way of reducing androgen hormones and is considered a more permanent solution to 
androgen deprivation.  Orchiectomy in addition to radical prostectomy can delay the progression 
of disease in patients with prostate cancer 79.  Most of the testosterone that is produced by a man 
is produced by the testis in response to luteinizing hormone produced by the anterior pituitary 
gland.  After bilateral orchiectomy, serum testosterone levels typically falls to castration levels 
(<10ng/ml) 79. 
A reduction in serum testosterone is associated with decreased fat free mass.  Mauras et 
al., reported that when serum testosterone was suppressed by the administration of gonadotropin 
–releasing hormone in healthy young men it was associated with significant reduction in fat free 
mass, increased fat mass, and a decrease in fractional muscle protein synthesis.  Likewise, an age 
associated decline in serum testosterone levels was correlated with reduced appendicular muscle 
mass and reduction in lower extremity strength in Caucasians and African Americans 80, 81. 
Current data on hypopituitary men suggested that hypogonadism is associated with 
abnormalities in body composition such as a reduction in lean body mass and elevation in fat 
mass82.  Katznelson et al., reported effects of hypogonadism in men who also had 
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hypopituitarism and observed a higher percent body mass and abdominal subcutaneous fat in 
hypogonadal men compared to healthy controls even after controlling for BMI.However visceral 
fat was not greater in the hypogonadal group compared to the eugonadal groups 83, 84.  Studies 
have also examined the relationship of androgen in elderly men such as bone mineral density and 
have found rather weak and inconsistent associations 85, 86. 
1.2.6.2 Prostectomy 
Another procedure that is sometimes recommended for the treatment of prostate cancer is radical 
prostectomy, which is typically recommended for the treatment of stage A, and B (Whitmore-
Jewett system staging system) prostate cancers.  This procedure generally requires a surgical cut 
through the abdomen or the perineal area and is done with general or spinal anesthesia 87.   
1.2.6.3 LHRH agonists 
The main drugs used for suppressing androgens are called luteinizing hormone-releasing 
hormones (LHRH) agonists.  LHRH drugs work by blocking the pituitary gland from producing 
hormones that stimulate the production of testosterone.  These drugs include Leuprolide 
(leupron, leuprogel) goserelin (zoladex), and buserelin.  Side effects from these drugs include hot 
flashes, nipple and breast tenderness, gynecomastia (breast enlargement) 77, 79. 
1.2.6.4 Antiandrogens 
Anti-androgens are drugs used to block the effects of testosterone.  The main anti-androgen 
drugs are: 
1. Flutamide (Eulexin, Drogenil).  Flutamide side effects include: diarrhea and liver damage 
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2. Nilutamide (Nilandron).  Nilutamide side effects include reversible interstitial 
pneumonistis, nausea, alcohol intolerance, and visual disturbances. 
3. Bicalutamide (Casodex). Bicalutamide seems to have fewer side effects compared to 
other anti-androgens 
4. Cyproterone combined with estrogen could prevent testosterone surge that typically 
occurs with LHRH. 
5. Other drugs. If patients are not responding to hormonal medications, other drugs that can 
be tried include estrogen therapy and ketoconazole (Nizoral) which is an  anti-fungal 
drug that blocks testosterone function in men 77. 
1.2.6.5 Chemotherapy for hormone resistant cancer 
For prostate cancer does not respond to hormone treatment chemotherapy may be use to treat 
hormone-resistant cancer.  Chemotherapy drugs for prostate cancer are: docetaxel (taxotere), 
mitoxantrone (novantrone), estramustine (Emcyt), andriamycin, paclitaxel and other platinum 
based drugs such as carboplatin.  These drugs are typically combined with other cancer dugs 
such as 5-fluorouacil, or corticosteroids (e.g. prednisone) 77.   
1.2.6.6 Untreated prostate cancer 
Information regarding patients who received no therapy for prostate cancer was evaluated in over 
3,000 men identified in the Connecticut Tumor Registry.  After diagnosis of prostate cancer 
these men either choose to receive no treatment or were advised by their physicians to receive no 
treatments. These individuals were followed for a minimum 15 years or until they died.  In this 
study the two major determinants of death because of prostate cancer were:  tumor grade and age 
at diagnosis.  This study reported that men with Gleason score of 7 or higher and who were 
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below the age of 74 years were more likely to die of prostate cancer.  On the other hand, men of 
all ages whose Gleason scores are 6 or lower have a low/minimal risk of dying from prostate 
cancer.  In summary, this study resulted in two important observations namely: Gleason 7 tumors 
and higher should be considered high grade tumors and that age at diagnosis seems to bear no 
significant impact on cancer-specific mortality after 15 years in individuals with low grade or 
high-grade tumors.  Age is more of a determinant in men with moderately differentiated tumors. 
32, 88 
1.2.7 ADT and body composition 
It is well documented that androgen deprivation therapy with GnRH (gonadotropin-releasing 
hormone) agonist is the mainstay treatment for metastatic prostate cancer.  Androgens are 
extremely important determinants of body composition in men. Studies have shown that GnRH 
agonist treatment increased weight and percentage fat body mass and decreased percentage lean 
body mass and muscle size in men 1.  Studies have also indicated that low serum testosterone 
concentrations are associated with decreased muscle mass and increased fat mass 89.  However, 
other studies have also shown that testosterone replacement therapy increases lean body mass in 
men with hypogonadism because of aging, HIV, and other chronic diseases 90-92.  In a 
prospective study that evaluated 48 weeks of GnRH agonist therapy in men with prostate cancer 
showed that these men experienced a 2.4% increase in weight, 9.4% increase in fat mass, and 
2.7% decrease in lean body mass. This increased fatness resulted primarily from the 
accumulation of subcutaneous rather than intra-abdominal adipose tissue 1. This effect on body 
composition could be related to testosterone deficiency because testosterone has been shown to 
promote lipolysis in visceral adipose tissue 93. 
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In addition ADT has been shown to produce other metabolic changes for instance:  
increased serum insulin levels, total cholesterol, low-density liproprotein, cholesterol, 
triglycerides and leptin1, 94, 95.  These abnormalities in lipid and glucose metabolism in addition to 
increases in body mass suggest that ADT could elevate an individual’s cardiovascular risk.  For 
example one study observed that after three months of GnRH agonist treatment participants had 
increased arterial stiffness in the radial artery and this problem resolved after treatment was 
discontinued 95.  However, because testosterone and estrogen both have direct and indirect 
effects on the vascular endothelium, it is not quite clear if the hemodynamic effects are related to 
deficiencies in one hormone or both 95.  Androgen deprivation therapy is also associated with 
fatigue, loss of energy, emotional distress and a poorer overall quality of life 96, 97. 
1.2.7.1 ADT and bone loss 
In a study by Greenspan et al. 98 men with prostate cancer who initiated hormonal suppression 
therapy had significant BMD loss at a various skeletal sites.  In this study there was greater bone 
loss after the first year of androgen deprivation therapy.  The observed reduction in BMD 
following 12 months of acute ADT was 1.5-4.0% depending on the skeletal sites measured in 
individuals.  Moreover, bone loss at the hips was related to the length of time that individuals 
were on ADT.  On the other hand, men with prostate cancer who had not initiated ADT and 
healthy controls had no significant bone loss over 12 months.  This study also observed an 
increase in percent body fat and a reduction in lean body mass in 12 months after the initiation of 
ADT.  Studies have shown that reduced muscle strength is an independent predictor of falls in 
the elderly.  Consequently reduced muscle mass may contribute a higher risk of fractures in men 
on ADT99. 
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Furthermore in a study that was conducted men on ADT had 47% lower estradiol levels 
than healthy controls and these levels were still considerably lower than those of men with 
prostate cancer but had not initiated ADT treatment (31% lower).  Treatment of prostate cancer 
with orchiectomy or GnRH agonist causes testosterone and its metabolite estradiol to fall 
significantly.  These hormones are important determinants of peak bone mass in men 100.  
However, estrogen is the dominant hormone that prevents bone resorption in men 101. 
Current suggested treatments to prevent ADT related bone losses in men are: Calcium 
and vitamin D supplement of 1200-1500mg daily.  In addition, individuals are encourage to 
abstain from negative habits that would exacerbate bone loss such as: smoking, excessive alcohol 
consumption, and a sedentary lifestyle 102.  Another potential option to reduce bone toxicity 
caused by ADT is the use of bisphosphonates.  Bisphosphonates are inhibitors of osteoclastic 
bone resorption103. 
1.2.7.2 Definition of osteoporosis 
Osteoporosis is considered a skeletal disorder that is characterized by decreased bone mass and 
also a deterioration of bone tissue ultimately resulting in fragility of bone and subsequent 
susceptibility to falls104.  Studies have shown that there is an inverse relationship between bone 
mass and fractures.  Osteoporotic fracture risk increases continuously as BMD decreases with an 
approximate 1.5 to 3-fold elevated risk of fracture for every standard deviation fall in BMD105.  
Osteoporotic fractures account for approximately 0.83% of the global burden of diseases 
worldwide106 . 
According to the World Health Organization, normal, osteopenia, and osteoporosis are 
based on BMD compared to the mean value in a young person.  Normal is defined BMD within 
1 standard deviation of the mean of a young adult person.  Osteopenia is defined as BMD 
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between 1.0 and 2.5 standard deviation below the mean of a young adult; and osteoporosis is 
defined as E:F(#8/$%&$0&#&.1-$/-+%8#4.2+G#/=.#6.$%#+,#$#5+9%>#$&92/F##@=.8.#6.$890.8#$0.#4$8.&#
on DEXA forearm BMD measurements and hip fractures in postmenopausal Caucasian women.  
However, because men have higher BMD and larger bones than women additional studies are 
needed in this area107. 
1.2.7.3 Osteoporosis gene polymorphism 
Due to the importance of family history and race genome wide linkage scans have been 
conducted to determine the genes that influence bone mineral density and osteoporosis.  
Association studies of the genetic effects of certain candidate genes on BMD and /or fractures 
have focused on the genes directly involved the metabolism of bone, structure, mineral and 
regulatory/hormonal pathways 108. Genes that have been involved in association studies are: 
estrogen receptor ('&#&(109, 110, vitamin D receptor 109-111, PTH receptor type 1110, interleukin 6 
112-114, insulin like growth factors 115, and alpha 2HS glycoprotein 111. 
1.2.7.4 Heritability of bone mass 
Genetics does play an important role in the determination of bone mineral density (BMD), and 
osteoporotic risk.  For instance in a comparison of monozygotic twins, dizygotic twins, offspring 
and parents it was determined that genetic factors play a key role in osteoporosis 116, 117.  Most 
studies demonstrated a heritability (h2) of approximately 50-80% for BMD at fracture sites such 
as the lumbar spine, hips and the radius 3, 118 but fracture heritability is considered more difficult 
to estimate with estimates of approximately 50% 119, 120.  An individual’s susceptibility to 
fractures depends on factors such as ones propensity to fall, non-skeletal factors, physical 
environment, and diminished soft tissue cushion. In addition, some heritability of fracture is 
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independent of bone mineral density 121, 122.  Studies have also shown that SNPs do contribute to 
variations in BMD but might not contribute to osteoporotic fractures 123, 124. 
Furthermore, studies have reported differences in the heritability of BMD in persons of 
the same and opposite genders 125.  This could possibly be explained by in-utero imprinting 
expressions of osteoporosis genes.  Other studies have found 20% greater heritability of BMD in 
men compared to women 126, 127 and some did not 128, 129.  A possible explanation for these 
gender specific heritability differences in BMD are our ability to account for environmental 
factors for instance estrogen in men 130, 131. 
1.2.7.5 Racial differences with BMD 
Osteoporosis is a serious public health problem that is associated with morbidity and mortality 
because of the risk of fractures. Fractures are usually associated with pain, limited mobility, and 
a reduced quality of life.  Data suggest that fracture risk is greater among Europeans compared to 
African Americans living in the United States 132.   
The Baltimore Men’s Osteoporosis Study examined racial differences in BMD, which is 
a longitudinal observational cohort study.  The study was comprised of 503 ambulatory white 
and 191 ambulatory African American men.  Men with bilateral hip replacement and excess 
weight of 300 pounds were excluded from the study.  Higher BMD at the femoral neck, lumbar 
spine, and total body of African American men were observed even with the adjustments for 
potential confounders.  Further analysis also showed that older African American men had 
narrower bone at the proximal femur and higher bone mineral content which is independently 
associated with greater bone strength 133.   
In the Third National Health and Nutrition Survey (NHANES III); osteoporosis was 
present in 5 and 20 percent of black women and white women age 50 and above at the femoral 
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neck; 8 and 17 percent at the total femur.  However, the prevalence of osteoporosis was 4 and 6 
percent in African American and European men at the femoral neck and total femur.  In this 
study prevalence of osteoporosis in men according to race varied depending on if female or male 
cutoff values were used.  Prevalence’s tended to be higher based on male cutoffs compared to 
female cutoffs 15, 132.   
Furthermore, in the Men’s Osteoporosis study decline in BMD was evaluated in 349 
European men and 119 African American men.  BMD measurements were taken at the proximal 
femur and the lumbar spine at approximately 18.8 months apart. The results indicated that the 
average annual percentage decline in BMD was significantly greater in European men than 
African American men at the femoral neck and total hip.  These observed differences persisted 
with the adjustment of known confounders: weight, age, and current smoking.  In this study 
current smoking was associated with greater bone loss in blacks and whites even with 
adjustments of: age, change in weight, and height 132, 134. Studies have also shown that African 
Americans have lower rate of bone turnover compared to European Americans 135, 136.  This 
lower rate of bone turnover H#2+G.0#&.*2-%.#-%#ADI#-%#J,0-*$%#J6.0-*$%8#-8#4.2-.1.&#/+#4.#/=.#
product of the combined effect of: nutrition, genetics, hormones, and lifestyle in adulthood 132. 
Bone strength in individuals is determined by a number of factors namely: mass and 
geometry of the bone, microarchitecture of the trabecular bone, the porosity of the cortical bone, 
composition of the bone matrix, and the accumulation of micro-damage in the bone.  African 
Americans seem to have greater mineral density compared to their European peers 132.  This 
observed higher bone strength in African Americans could be the result of: a stronger skeleton 
during early childhood and adolescence, and slower bone loss in adulthood 132.  Moreover, 
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studies have shown that African American children had greater bone mass than European 
children and these results continued into young adulthood in males 137, 138. 
1.2.8 Androgen receptor (AR) 
Androgen receptor (AR) is an intracellular transcription factor that is a member of the steroid 
nuclear receptor super family 139, 140.  The androgen receptor gene (AR) contains in N-terminal of 
exon-1 a polymorphic trinucleotide CAG repeat (encodes polyglutamine), whose length 
regulates androgen receptor action.  Included in this region is another trinucleotide repeat GGC 
which codes for glycine141.  AR is activated by androgens and then translocated to the nucleus 
where it binds to DNA sequences called androgen response elements located in regulatory region 
of androgen dependent genes.Furthermore, the binding of androgen-AR complexes does one of 
two functions it either represses or activates androgen –regulated proteins 142.  Hence, ARs are 
very important molecular switches that control transcription of androgen-dependent proteins 
during embryogenesis until adulthood.  The AR gene, located on the X chromosome at Xq11-12 
143, is encoded in eight exons144 and has three functional domains namely: the transactivation 
domain (TAD), DNA binding domain and ligand binding domain 145.  Differences in the AR 
sequence are mostly characterized by polymorphic trinucleotide repeat (CAG) and the normal 
length of a CAG is approximately 9-37 146, 147.  The transactivational activity of AR is inversely 
related to the length of the CAG repeat chain In addition, because the androgen receptor is 
located on the X-chromosome males have only one copy 148. 
The androgen receptor is sometimes mutated in prostate cancer with varying effects on 
functionality and on activating steroid and non-steriodligands.Evidence for the importance of 
CAG AR repeat lengths are that: men with 40 or more CAG repeats suffer from Kennedy 
Syndrome (spinobulbar Ataxia) which is characterized by androgen insensitivity, and 
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progressive muscle weakness 144, 149.  Men with longer CAG repeats are more likely to have 
reduced spermatogenesis than men with shorter repeats 150.  One study found that men with 
prostate cancer had shorter CAG repeats which were associated with being African American 
and a higher and more aggressive prostatic carcinoma 151.  In addition, shorter repeats are 
associated with a higher risk of benign prostatic hyperplasia (BPH).  BPH is characterized by 
overgrowth of the tissue of the transition zone and the periurethral area of the prostate 152.   
1.2.8.1 Ethnic differences in AR CAG repeat length 
Within the normal range of the AR polyglutamate, ethnic differences have been reported.  For 
instance, in healthy men of African descent the average number of CAG repeats reported is 
between 18 and 20 13, 147 and is somewhat shorter in other African populations 153.  In Caucasians 
the average number of CAG repeats is 21-22 13, 147 whereas in East Asians a mean of 22-23 was 
observed 146, 147, 154. 
1.2.8.2 AR CAG repeat length and BMD 
Studies have shown that in healthy men, polymorphism of the oestrogen receptor regulate 
quantity and quality of bone tissue155 and this is also applicable to CAG repeat 
polymorphismsfound in the AR gene.  In 110 males age 20-50 years an increased number of 
CAG AR repeats was associated with low bone density65 and the results of this study was further 
corroborated by a study conducted inperi-menopausal women 156.  
However, results in older men are somewhat conflicting.In a study of 508 Caucasian men 
65 and over a negative association between AR CAG repeat length and bone mineral density of 
the femoral neck was observed 111.  But in this same group, a more pronounced bone loss was 
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observed at the hip and an increased risk for vertebral fracture was reported in men with longer 
AR CAG repeat length 111.   
In a cohort of 273 Belgian men age 71 and 86 years no influence of AR polymorphism 
was observed 141. It is hypothesized that higher androgenization will cause greater peak bone 
mass131, and AR polymorphism effects on bone densitywill only be evident in healthy younger 
men.  This difference in AR polymorpisms effects could be mitigated because of age-dependent 
bone loss in older men caused by confounders that exerted some influence on bone mass 62.  In 
another study, that evaluated the effects CAG repeat polymorphism on bone density and 
metabolism, determined that increasing number of CAG repeats in the AR gene influence on 
bone density and bone metabolism is attenuated in healthy males.  In this study CAG repeat 
polymorphism accounted for 8% of total variation of bone density; which suggests that the 
number of CAG repeats in the AR is a determinant of bone density in healthy men.  
Consequently one could speculate that a mild deficiency in testosterone is associated with 
negative effect on bone density in individuals with long CAG repeats sequence.  While persons 
with shorter CAG triplets show no sign of bone loss for comparable testosterone levels 157.  
Hence, longer CAG repeats in the AR gene will lead to lower peak bone density in men. Clearly, 
more studies are needed to elucidate the relationship between CAG AR and bone mineral density  
1.2.8.3 AR CAG repeat length and body composition 
Testosterone has shown conflicting associations with cardiovascular risk factors.  Low levels of 
testosterone can have unfavorable effect on body composition, insulin sensitivity 57 and 
haemostatic parameters158.  Studies have shown that androgen has a lowering effect on good 
cholesterol (HDL)159.  Furthermore, studies on the role of testosterone on vascular endothelial 
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function have shown a negative effect but these results were contradictory and appear to be 
contingent on endogenous hormone levels and how artificial testosterone was administered64.   
In a study of 110 men age 20-50 years CAG repeat polymorphisms decreases testosterone 
effect on HDL cholesterol and flow mediated dilation of the brachial artery.  A longer 
polyglutamine stretch in the AR protein is associated with a higher cholesterol levels and arterial 
vasoreactivity64.  Similar findings were also reported in patients who suffered from XSBMA (X-
linked spino-bulbar muscular atrophy)160.  It is quite possible that longer CAG repeats in the AR 
gene could possibly act as a cardio-protective factor but the receptor polymorphism might play a 
role in determining a person’s atherosclerotic risk. It has been reported that in men with longer 
CAG repeats also had higher body fat and also insulin resistance 62.  Similarly, in patients with 
XSBMA they had a tendency to develop diabetes mellitus 161. 
1.2.8.4 !"Adrenergic Receptor 
Adrenergic receptors are members of a large super family of cell surface receptors that are 
involved in signaling via coupling to guanine nucleotide binding proteins (G-proteins). 
Adrenergic receptors are targets for epinephrine, catecholamines and norepinephrine and are an 
important component of the sympathetic nervous system for the maintenance of homeostasis and 
response to disease.  Human adrenergic receptors consist of nine subtypes: '1A-, '1B-, '1DAR; 
'2A-, '2B-, '2CAR; #1, #2, and #3AR 162, 163.  Four of these results in changes in the amino acid 
sequence: glycine-for-arginine substitution at codon 16 (Arg16Gly), glutamic acid-for-glutamine 
substitution at codon 27 (Gln27Glu), the methionine-for-valine substitution at codon 34 
(Val34Met) and threonine-for-isoleucine substitution at codon 164 (Thr164Ile) 164.  The human 
#2-adrenoceptor is located on chromosome 5q31-32 165. 
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A variability in a DNA sequence with an allele frequency of >1% in the population is 
denoted a polymorphism.  Polymorphisms may have no effect, or have clinically silent effects, or 
could modify diseases or alter response to therapy, act as low level risk factors, and have 
increased prevalence in particular diseases.  The most common type of polymorphism is single 
nucleotide substitution termed SNPs.  Within the coding regions of genes, polymorphisms 
encode different amino acids (nonsynonymous polymorphisms).  Polymorphisms occur in the 5’ 
UTR, promoter, 3’ UTR and introns163.  
1.2.8.5 #2 adrenergic receptor and hypertension 
K/9&-.8# =$1.# 8=+G%# /=$/# /=.# L2-adrenergic receptor is involved in vascular smooth muscle 
relaxation and vasodilation in response to the release of epinephrine 85, 166.  For instance, the 
-67$-06.%/#+,#L2-adrenergic receptor-mediated vasodilation in the presence of normal or elevated 
vasoconstrictor response causes an increased vascular reactivity and also raises blood pressure.  
B90/=.06+0.M# 429%/.&# L2-adrenergic receptor-mediated vasodilation has been observed in 
hypertensive individuals 167-169 -%&-*$/-%># /=$/# $//.%9$/.&# L2-adrenergic receptor could be 
important in the pathogenesis of essential hypertension.   
Even though, the mechanism is not fully understood, it is well known that hypertension is 
typically more severe and associated with higher rates of morbidity and mortality in African 
Americans compared to Caucasians 170-172. 
N%# $&&-/-+%M# -/# =$8# 4..%# &.%+/.&# /=$/# 1$8*92$0# L2-adrenergic receptor responses were 
attenuated in blacks considered normotensive173 implying that an attenuated vasodilator response 
might play a key role in the development of hypertension in Blacks174. 
O.%./-*# 8/9&-.8# -%&-*$/.&# /=$/#L2-adrenergic receptor could play a key role in increased 
hypertension and the risk of hypertension.  It was denoted in an association study, that the gene 
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.%*+&-%>#L2-adrenergic receptor was associated with the development of essential hypertension 
175F##P-Q.G-8.M#8$2/#8.%8-/-1-/5#G$8#,+9%&#/+#4.#$88+*-$/.&#G-/=#L2-adrenergic receptor in African 
Americans 176. 
However, the 0.2$/-+%8=-7# 4./G..%# L2-adrenergic receptor polymorphism and 
hypertension still remains somewhat unclear.  For instance, Gly16 polymorphism occurred more 
frequently in hypertensive Afro-Caribbean’s177while in blacks from South Africa no association 
was found between Arg16-Gly and/or Gln27-O29# L2-adrenergic receptor polymorphism and 
essential hypertension 95.  However, in a cohort of Germans Arg16 increased the predisposition 
of hypertension 178. 
Consequently, it i8# .1-&.%/# /=$/# /=.# 0.2$/-+%8=-7# 4./G..%# L2-adrenergic receptor 
polymorphism and ethnicity and hypertension is poorly understood and further studies are 
needed to elucidate this relationship.  Clearly, evaluating this relationship in Afro-Caribbean men 
woul&#*+%/0-49/.#8->%-,-*$%/25#/+#/=.#2-/.0$/90.#$%&#/+#*900.%/#Q%+G2.&>.#$%&#9%&.08/$%&-%>#+,#L2-
adrenergic receptor polymorphism in hypertension. 
1.2.8.6 #2 adrenergic receptor and body composition 
There have been studies showing a putative association between obesity and L2-adrenergic 
receptor. The L2-adrenergic receptor genes have been studied because of their key roles in the 
regulation of energy metabolism and utilization 179.  The #2-adrenoceptor plays important roles in 
the regulation of energy homeostasis, for instance the stimulation of glycogen breakdown and 
lipid mobilization.  #1 co-exist with #2 and #3adrenoceptors in the white adipose tissue 164, 180.   
Gln27Glu variant influences body fat by changing the lypolytic response of adipose 
tissue to catecholamines.  Catecholamines are lipolysis stimulating hormones 180, 181.  Gln27Glu 
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is associated with a relative risk of obesity H#R#$%&#+&&8#0$/-+#+,#H#ST# 179.  The role of #2-receptor 
gene polymorphism for obesity has so far been mainly evaluated in women 179.  Women who are 
homozygous for Glu27 have been found to have 20kg more fat mass compared to controls.  
Carriers of Glu27 had 50% larger fat cells compared to non-carriers 179.  This polymorphism has 
also been found to be associated with obesity in the Swedes 182 linked to obesity in the Japanese 
183 and is associated with the early onset of obesity in the Danes 184.  Interethnic differences have 
also been observed in allele frequencies.  The Glu27 variant has been found to be more common 
in European Americans than African Americans 174.   
1.2.9 Obesity in the Caribbean 
The epidemic of obesity in the Caribbean has become a major health care problem. In the 
Barbados population between 1968 and 1981 obesity increased from 7.0 to 16.2% in males and 
31.0 to 37.9% in females. In women over the age of 40 years the prevalence of obesity increased 
from 32% to 50%. Furthermore, in Jamaica over a 33 year span (1962-1995) the prevalence of 
obesity increased from 2% to 25% in men and 30 to 60% in women185.  
Obesity in the Caribbean is a major concern and has been shown to be more prevalent in 
countries with a higher per capita gross national product (GNP) and it seems to 
disproportionately affect women.  Studies conducted in Jamaica, Barbados, Nigeria, Cameroon, 
St. Lucia and Maywood have demonstrated that hypertension increases in a manner similar to 
that of obesity 185.  The prevalence of these chronic diseases are greater in lower income 
individuals from poorer countries who start living a westernized lifestyle influenced by 
sedentism, and caloric dense foods186.  Similar to United States obesity in the Caribbean plays an 
important role in the pathogenesis of T2DM, hypertension and negative body composition 
changes.  It has also been demonstrated that diabetes mellitus frequently coexists with other 
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conditions such as abnormal serum cholesterol which is a symptom of the metabolic 
syndrome187. 
1.2.9.1 Causes of weight gain 
Obesity typically occurs when there is an increase in energy consumption compared to energy 
expenditure 188-190 .  Dietary surveys show an increase in caloric intake in the United States of 
approximately 200kcal/day in the past 20 years 191, 192.  Much of this caloric intake corresponds 
to the increase consumption of fats, sugars, fast foods, snacks, high caloric beverages, larger 
food portion sizes and eating outside the home193.  For instance, meals at fast food restaurants 194, 
full service restaurants 195, and eating between meals have been shown to cause an increase in 
body weight 193, 196. 
1.2.9.2 Energy output: physical activity 
In 2002 the Center for Disease Control (CDC) and Prevention determined that approximately 
less than 30% of individuals in the United States were engaging in sufficient physical activity. 
While an additional 30% of persons were active but not sufficiently with the remainder of 
individuals predominantly sedentary engaging in minimal levels of physical activity 191, 197. 
The percentage of the population that reports participating in no leisure time physical 
activity is greater amongst women compared to men, greater in African Americans, and 
Hispanics compared to European Americans, higher among older adults compared to younger 
adults and greater in the less affluent compared to the more affluent in society 198.  It has been 
shown that individuals with lower levels of education and income engage in less leisure time 
physical activity 198.  Studies have also demonstrated that individuals who are moderately or 
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highly active have a longer life expectancy and have more years free of chronic diseases such as 
diabetes 199. 
1.2.10 Distribution of body fat 
Obesity related changes are significantly related to an accumulation of fat in the body, and in the 
literature there is substantial evidence indicating that central obesity is a stronger predictor of 
morbidity than the accumulation of fat in the lower body 200, 201.  The accumulation of fat in the 
in the abdominal regions has significant implications for metabolism and insulin sensitivity 201.  
These co-morbidities are more related to waist circumference than to BMI.  Additionally, 
visceral or abdominal fat is strongly associated with an elevated risk of cardiovascular disease 
and type 2 diabetes 202.  Visceral adiposity is considered a risk factor for cardiovascular disease, 
insulin resistance, metabolic syndrome and T2DM in adults 203, 204.   
1.2.10.1 Subcutaneous and visceral fat 
Intra-abdominal fat has been shown to be linked to an increased risk of developing debilitating 
diseases.  Adipose tissue that is located in the abdomen is comprised ofboth visceral and 
subcutaneous fat; and there has been some discrepancy regarding the contribution of these 
compartments to the development of the metabolic syndrome in overly obese individuals. 
Studies have shown that there is a positive relationship between abdominal subcutaneous fat and 
the development of insulin sensitivity 205.   
Many researchers report that visceral adipose tissue is a stronger determinant of insulin 
resistance compared to subcutaneous adipose tissue. Studies have shown that both visceral and 
subcutaneous fat are related to insulin sensitivity 206. It has also been shown that the amount of 
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subcutaneous fat is strongly associated with the level of insulin resistance and increasedlipolytic 
rates compared to the superficial subcutaneous abdominal fat 207. 
1.2.10.2 Intramuscular fat 
Studies have revealed that the location of fat within the thigh determines disease risk 208.Fat 
stored in the non-subcutaneous regions (meaning fat located in the muscle or around muscle 
fibers) was related to insulin resistance in persons considered obese; however, there was no 
correlation with subcutaneous thigh fat 208. In addition, a positive association has also been 
observed between insulin resistance and intramuscular lipid levels 209, 210.   
Krssak et al.,209  has shown that intracellular lipid concentrations were correlated with 
insulin sensitivity using novel proton nuclear magnetic resonance spectroscopy technique (H 
NMR) 209.  In addition, Goodpaster et al.,208 revealed that sub-facial adipose tissue and 
intermuscular adipose tissue are markers of insulin resistance in obese persons and type II 
diabetics. However, some but not all studies delineated a relationship between skeletal muscle 
lipid and insulin sensitivity. One study of older normoglycaemic women found that intracellular 
lipid content was inversely correlated with insulin sensitivity 210.  Intracellular lipid however was 
shown to be related to waist hip ratio and fasting plasma concentrations of non-esterified fatty 
acids (NEFA) but not with glucose tolerance or whole body insulin sensitivity 210. Another study 
reported an inverse correlation between muscle triglyceride and insulin sensitivity 211. 
Fatty acid concentration of the cell membrane in the skeletal muscle affects insulin 
sensitivity by altering the physicochemical properties of the membranes, which alters receptor 
function, ion transport over the membrane, cell energy requirement and cell signaling.  In 
addition, elevated levels of saturated fatty acids in the cell membrane disrupts insulin action by 
altering insulin receptor binding, altered ability to translocate or insert glucose transporters, 
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changing phospholipid fatty acids-interaction with function of second messenger (protein kinase 
C) and reduced ion permeability 212.  
1.2.10.3 Waist circumference (WC) and waist to hip ratio (WHR) 
Waist and hip circumference ratios are important measurements of the abdomen as well as in 
predicting abdominal obesity 213.  The values of the waist-to-hip circumference ratio (WHR) 
used to define abdominal obesity are 0.95 for men and 0.80 for women. There is evidence 
suggesting that waist circumference (WC) is a better clinical measure of abdominal obesity than 
WHR 214. A potential limitation of WHR is, it might not change when the hip and waist 
circumference increase by comparable ratios.  Consequently, WHR is typically inaccurate in the 
event of significant loss of visceral adipose tissue 215.  
There have been a few studies that have suggested that WC and WHR predicts abdominal 
adipose tissue equally well.  However, current data are more in favor of using WC as a better 
measure of abdominal fat 216, 217.  WC predicts percentage body fat which correlates well with the 
development of insulin resistance and the development of cardiovascular risk factors in African 
Americans, European Americans and Europeans 218-221. Moreover, the interpretation of these WC 
values depends on the race/ethnicity of the group under evaluation.  Caribbean populations, such 
as Jamaica, Nigeria, St. Lucia, Barbados and Cameroon the predictive values of established cut-
offs of WC showed poorer sensitivities for abdominal obesity 222.   
1.2.10.4 Body mass index (BMI) 
Body mass index (BMI) is a statistical measurement, which compares a person's weight and 
height. The BMI is a useful tool to estimate a healthy body weight based on how tall a person is, 
however; it does not measure the percentage of body fat. This measure of general adiposity is 
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defined as weight in kilograms (kg) divided by height in meters2. According, to the WHO a BMI 
<18.5 kg/m2 is defined as underweight, 25-29.9 kg/m2 is considered overweight and ECT#Q>U62 is 
defined as obese 191, 223, 224. Several studies have shown that abdominal circumference is highly 
correlated with increased risk of type 2 diabetes than BMI 225.  Although, BMI is one of the most 
common measures of assessing general obesity in adults, Other measures such as dual X-ray 
absorptiometry (DEXA), Quantitative computerized tomography (QCT), computed tomography 
(CT) and peripheral quantitative computerized tomography (pQCT) can provide more accurate 
measures of body fat or the percentage body fat in an individual 226.  
1.2.10.5 Visceral fat as a pro-inflammatory tissue 
Visceral fat shows evidence of accelerated lipolytic activity with an elevated release of free fatty 
acids that can severely affect insulin action and glucose diffusion in many tissues 227-230. These 
elevated levels in circulating FFAs may also cause an increase in triglyceride reservoirs in the 
muscle and liver decreasing insulin action and elevating hepatic very low-density protein output 
231, 232.   
On the other hand, a reduction in visceral adiposity and FFA levels after weight loss has 
been associated with enhanced insulin sensitivity 233, 234.  Visceral fat has been shown to be 
0.87+%8-42.#,+0#/=.#0.2.$8.#+,#*5/+Q-%.8M#89*=#$8#/96+0#%.*0+8-8#,$*/+0#V#?@WB-V3#$%&#-%/.02.9Q-%#
6 (IL-6) 235, 236.  TNF-V#-%=-4-/8#/50+8-%.#Q-%$8.7=+87+052$/-+%#+,#/=.#-%892-%#0.*.7/+0M#*$98-%>#$#
defect in insulin signaling contributing to insulin resistance and impaired glucose transport 237.  
An imbalance of proinflammatory cytokines from adipose tissue can trigger C-reactive protein 
(CRP) secretion.  It has been shown that CRP levels are strongly associated with insulin 
resistance and adiposity, and elevated levels of CRP has been shown to be correlated with 
impaired endothelial dysfunction and CAD 238.  
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1.2.10.6 Race ethnicity and body fat distribution 
There have been several studies that have shown that body fat distribution varies according to 
population.  These differences in body fat distribution were found to be associated with elevated 
triglycerides, high blood pressure, low HDL cholesterol, and high glucose levels.  Studies in the 
United States and South Africa have indicated that visceral fat is smaller in African Americans 
compared to Europeans matched on BMI.  However, it has been noted that in the black 
populations, individuals are more insulin resistant compared to European populations 239-241. 
Abdominal fat contributes different degrees of risk for hypertension depending on the 
ethnicity of the person.  For instance, compared to Europeans, black men and women have a 1.58 
and 1.39 greater risk of developing hypertension if their waist circumference values are 
extremely high 242.  Likewise, the clustering of insulin resistance syndrome associated with 
abdominal obesity seems to occur more frequently in Black and Hispanic individuals 243.  
Depress et al.,244reported that with comparable levels of fatness, Europeans appeared to have 
more abdominal fat compared to African Americans.  African American women appear to have 
higher levels of total body fat but similar abdominal adipose tissues as their European 
counterparts.   
1.2.11 The metabolic syndrome 
The term metabolic syndrome is defined as the clustering of cardiovascular risk factors related to 
hypertension, abdominal obesity, dyslipidemia, and insulin resistance.  According to the National 
Cholesterol Education Program Adult Treatment Panel ATP III guidelines in 2001, metabolic 
syndrome is the presence of three or more of the five risk factors.  Other characteristics of the 
metabolic syndrome are: hyper-insulinemia, insulin resistance, and higher density of LDL 
cholesterol.  The metabolic syndrome is also associated with elevated levels of inflammatory risk 
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markers, such as fibrinolysis, plasminogen activator inhibitor-1, oxidative stress, 
microalbuminuria, irregularity in autonomic regulation, and the activation of the rennin 
angiotensinaldosterone axis 245. 
1.2.11.1 The impact of ethnicity on the metabolic syndrome 
Ethnicity has a major impact on metabolic and anthropometric changes as well as co-
morbid diseases.  A major component of the metabolic syndrome is obesity. In South Africa, 
obese Black women matched for BMI and body composition were compared to obese urban 
European Caucasian women and their metabolic differences and #%cell function examined.  The 
Black women had a higher degree of insulin resistance, lower plasma insulin and C-peptide 
levels, reduced anti-lypolytic activity, higher post absorptive FFA concentrations, lower fasting 
and 3-h triglyceride concentrations, and lower plasma cortisol concentrations 240, 241, 246-251. 
Other studies have shown that black women have less visceral fat and black diabetics 
have higher fat mass compared to obese black women without diabetes with similar BMIs.  
These studies also showed that weight loss occurred more swiftly in the glutofemoral regions in 
black women, but weight loss in the visceral regions occurred in both groups.  This weight loss 
that occurs in the in black women might be the result of greater lypolytic activity in the 
glutofemoral regions 252, 253.  On the other hand, the visceral fat in obese European women has 
been shown to be associated with more atherogenic fasting and postprandial lipid profiles 240, 247, 
248, 253.  
 Similar findings were also observed in fit men as that observed in obese women. For 
example plasma insulin and postprandial glucose tolerance were lower in lean black men 
compared to European Caucasian men.  Lypolytic activity was also elevated in lean black men 
compared to lean European Caucasian men 253.  
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1.2.11.2 Prevalence of the metabolic syndrome 
According, to the NHANES data (1988-1994) the prevalence of the metabolic syndrome in the 
United States was estimated to be approximately at 23.7 percent or approximately 47 million 
people have this problem.  In the United States the metabolic syndrome is expected to increase 
exponentially.  Prevalence of the metabolic syndrome was defined according to ATP III EC#+,#
the abnormalities: waist circumference greater than 102 cm in men and 88 cm in women; serum 
triglycerides level of 150 mg/dL (1.69 mmol/L); high density lipoprotein cholesterol level of less 
than 40 mg/dL in men and 50 mg/dL in women; blood pressure of at least 130/85 mm Hg; or a 
serum glucose level of 110 mg/dL.  The unadjusted and age adjusted prevalence of the metabolic 
syndrome were 21.8% and 23.7% percent respectively.  The prevalence of the metabolic 
syndrome increased from 6.7% in adult’s age 20 years to 29 years to 43.5% and 42% for 
individuals 60 to 69 years. Mexican Americans had the highest age adjusted prevalence of the 
metabolic syndrome (31.9%).  The age-adjusted prevalence was similar for men (24.0%) and 
women (23.4%).  But African American women had 57% higher prevalence than men 254. 
In men the metabolic syndrome (MetSyn) is associated with a fourfold elevated risk for 
CHD, a twofold risk of CVD and all cause mortality even with adjustments for age, LDL-
cholesterol, smoking, and a family history of CHD. Likewise, the metabolic syndrome in women 
is associated with an increased risk of CHD.  Individuals with the metabolic syndrome are five to 
nine times more likely to develop diabetes.  However, in the PROSPER study, the metabolic 
syndrome and its individual components were not associated with the development of CVD but 
the presence of the metabolic syndrome at baseline was associated with a future risk of 
developing diabetes especially in individuals with a BMI >30kg/m2 and a fasting a glucose of 
>6.1 mmol/L 255.  Similarly, in the BRHS study, the metabolic syndrome was weakly associated 
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with the development of CVD events but its individual’s components such as waist 
circumference, serum triglycerides, HDL cholesterol, elevated blood pressure, and fasting 
glucose were associated with an increased risk of developing diabetes 255.  Hence, these results 
suggest that the metabolic syndrome is strongly associated with the development of diabetes in 
the middle age and also the elderly but is weakly associated with CVD 255. 
In the St. James Coronary Risk Factor study, African Trinidadians had lower cholesterol 
and LDL cholesterol and higher HDL cholesterol than Asian Trinidadians.  It is believed that a 
large percentage of this population has at-least three maybe four of the characteristics considered 
the deadly quartet or Raven syndrome X: which are obesity, hypertension, diabetes, glucose 
intolerance and hyperlipedemia256-259. 
1.2.11.3 Lifestyle modification 
According to the SMART study regular exercise reduced the risk of developing metabolic 
syndrome by at least 50% and these results remained significant even without weight loss in 
individuals.  In this cohort insulin resistance was inversely correlated with physical activity on 
the homeostasis model assessment (HOMA)260.  Furthermore, exercise reduces adiposity and 
weight while improving insulin sensitivity.   
Lakka et al.,261 reported that in the HERTAGE study physical activity reduced markers of 
inflammation for instance C-reactive protein. It is believed that physical activity improves the 
risk factors for insulin resistance and hypertension by inhibiting the production of cytokines and 
their potential interaction with monocytes and endothelial cells261, 262. 
Dietary modifications are also helpful in treating insulin resistance and hypertension.  For 
instance, a heart-healthy diet lowers levels of TNF-V#263.  In the Framingham offspring cohort a 
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diet high in whole grains and fiber reduced the risk of developing insulin resistance and the 
metabolic syndrome 264.  
The ARIC (atherosclerosis risk in communities) study reported that a western diet 
increases the risk of developing the metabolic syndrome by 18%.  This study reported that the 
consumption of meats, fried foods, and the regular intake of diet sodas was associated with 
increased risk of the MetSyn265.  However, diary products were inversely associated with 
MetSyn both cross-sectionally266-268 and prospectively 267. No association was found between the 
association of the MetSyn and whole grains, refined grains, fruits, vegetables, nuts, coffee and 
sweetened drinks 265.  
Final,the DASH diet, which is considered to be rich in fruits, vegetables, low fat dietary 
products, sweeteners and reduced consumption of meats, reduced the risk of developing the 
metabolic syndrome and hypertension 269. Exercise does provide some protection against the 
metabolic syndrome and also hypertension. Individuals who lost weight showed a reduction in 
their mean arterial pressure, plasma renin activity and aldosterone levels 156. 
1.2.12 Measurement of body fat distribution 
1.2.12.1 Dual X-ray absorptiometry (DEXA) 
DEXA scans are primarily used to evaluate bone mineral density, measure total body 
composition and fat content. The speed of DEXA, its easy use, relatively low costs and lower 
radiation compared to computed tomography (CT) makes it good a method for use in clinical 
settings, research, and also in large population studies.  The DEXA machine uses two-X-ray 
beams with differing energy levels. When soft tissue absorption is subtracted out, the BMD can 
be determined from the absorption of each beam by bone 270, 271.   
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1.2.12.2 Computed tomography (CT) 
Computed Tomography Imaging can be used to quantify a cross sectional area of tissue.  CT 
distinguishes tissue in vivo based on the level of which they attenuate the energy of an X-ray. 
These attenuation processes depend substantially on their density and are expressed in 
Hounsfield units (HU), positive for muscle and negative for fat. Adipose tissue is not as dense as 
water and hence displays attenuation values that are of a negative value.  However, muscle is 
denser than water and consequently would have more positive attenuation values272. CT is a very 
important method for quantification of visceral fat. 
1.2.12.3 Quantitative computerized tomography (QCT) 
Historically quantitative computerized tomography (QCT) was used to measure volumetric bone 
density of the spine and hip. QCT also analyzes the cortical and trabecular bone separately 270. 
This method has been proven to be quite useful in clinical research settings and also used to 
evaluate patient progress particularly therapeutic responses to parathyroid hormone therapy.  Even 
though this method has mainly been used to determine bone mineral density of the periphery it 
can also be used to measure body fat.   
1.2.12.4 Peripheral quantitative computerized tomography (pQCT) 
Peripheral quantitative computerized tomography (pQCT) is used to measure peripheral sites 
272.PQCT has been used to determine body fat in mice.  The accuracy of the values obtained 
from PQCT was compared to chemical extraction in mice.  The coefficient variation for 
determining percentage body fat in mice using PQCT was 3.9% (±1.8SD). PQCT was considered 
to have good accuracy and also precision in determining percentage body fat and liver fat in 
animals studies273.  Ranke et al.,274determined that the use of PQCT was a suitable technique to 
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determine the size, the structure of muscle, fat and bone in pubertal girls with Turner syndrome 
who were being evaluated on the effects of growth hormone therapy.   
1.2.13 Diabetes 
1.2.13.1 Prevalence of diabetes in the United States 
Current data show that the prevalence of diabetes in the United States has risen 40% from 4.9% 
in 1990 to 6.9% in 1999 275.  Type 2 diabetes mellitus is 10 times more common in adults over 
the age of 65 years compared to those younger than 45 years of age 275.   
In addition, T2DM is more common in minority racial groups such as: Native Americans, 
Hispanics, and African Americans.  This disease affects these groups at a rate 2-4 times 
compared to European American populations.  This increased prevalence of T2DM has been 
reported in adolescence and children, T2DM mellitus tend to occur more frequently than type 1 
diabetes 275.   
In the United States the estimated lifetime risk of developing T2DM in 2000 was 33% for 
males and 39% for females 275. T2DM is also associated with reductions in life expectancy of 11 
years in males diagnosed after the age of 40 years 276. 
1.2.13.2 Pathogenesis of diabetes 
Glucose is considered the body’s main source of energy and in most mammals there is a cell 
membrane protein that facilitates the diffusion of glucose from the blood stream following the 
digestion of food into the cell.  A gradient is maintained facilitating the diffusion of glucose into 
the cell by phosphorylation of sugar once it enters the cytoplasm lowering intracellular glucose 
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concentration. There are several proteins that facilitate the transportation of glucose and these 
isoforms and they are termed GLUT1-5 distinguished by the tissues in which they are found 277.   
N%892-%#-8#$#=+06+%.#70+&9*.&#45#/=.#.%&+*0-%.#*.228#+,#/=.#7$%*0.$8#?L-cells) and plays 
an important role in the maintenance of blood sugar levels.  An elevation in blood glucose levels 
triggers the release of insulin, which stimulates the uptake of glucose into target cells such as the 
skeletal muscle and adipocytes.  When insulin levels rise in response to elevated blood glucose 
levels this hormone acts on target cells and stimulates the translocation of glucose into the cell. 
Diabetes is caused by a defect in insulin activity277.  The glucose transporter GLUT4 mediates 
insulin uptake in adipocytes and also in muscle cells by moving glucose from intracellular 
storage sites into the plasma membrane 278. 
In persons who are not diabetic normal plasma glucose range is between 4 and 7 mM.  
This maintenance of normal glucose levels is governed by a balance between glucose absorption 
from the intestines and its production by the liver and its metabolism by the peripheral tissues.  
As mentioned before insulin increases glucose uptake in muscle and fat, and inhibits hepatic 
glucose production consequently acting as the regulator of blood glucose concentrations.  
Likewise, insulin fuels cell growth and differentiation, and enhances the storage of substrates in 
fat, liver and muscle through the process of lipogenesis, glycogen, and protein synthesis, and also 
through the inhibition of lypolysis, glycogenolysis, and the breakdown of proteins 279.  
T2DM is a non-autoimmune disorder.  Patients with T2DM have insulin resistance as 
well as a significant reduction in insulin response to glucose.  Cross-sectional studies have 
demonstrated that high risk groups have severe reductions in insulin sensitivity and or defects in 
L-cell function or they may have abnormalities in both path ways 280.  Studies have indicated that 
older individuals are at an increased risk of developing type II diabetes.  Typically because these 
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patients have impairments in postprandial rather than fasting glucose281.  It is believed that a 
significant number of individuals that were originally diagnosed as type 2 diabetics were cryptic 
type 1 diabetics who later evolved to a type 1 state denoted as anti-L-cell autoimmunity 282. 
1.2.13.3 Obesity and insulin resistance 
Insulin resistance is denoted as, “reduced insulin-mediated glucose uptake in insulin sensitive 
tissues such as skeletal muscle and liver” 283.  In individuals who are obese, insulin resistance is 
common and is typically related to central abdominal fat.  Much of the fat located in the central 
abdominal region is called visceral adipose tissue (VAT).  VAT is related to insulin resistance 
and the metabolic syndrome.  This fat is mostly comprised of mesenteric and omental fat masses 
that can be measured through a variety of diagnostic measures such as CTs, MRIs and DEXA 
scans.  Visceral adipose tissue accounts for a small proportion of total fat in the body namely 
10% whereas 25% to 50% of abdominal fat is subcutaneous. However, many researchers believe 
that it is VAT that confers a risk for insulin resistance because it has a higher lipolysis rate than 
SAT and also because of it close proximity to the portal circulatory system 284. 
1.2.13.4 Adipocytes, insulin resistance and diabetes 
Adipose tissue is considered an extremely active metabolic and endocrine organ that participates 
in a variety of homeostatic processes that produces hormones such as leptin, adiponectin, 
0.8-8/-%M# @WBVM# $%&# NP-6 which influence insulin sensitivity and plays a key role in the 
pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation and atherosclerosis 285-
288F##P-Q.G-8.M#$&-7+*5/.#&.0-1.&#,$*/+08#*+%/0-49/.#/+#/=.#&.1.2+76.%/#+,#L-cell dysfunction and 
also type 2 diabetes 289. 
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Adiponectin is a protein and also an adipose tissue-specific collagen like factor 290 that is 
secreted by adipocytes and can be found in concentrations of 7 to 12mg/L in healthy 
individuals.It has been shown that adiponectin strongly correlates with decreased fatty acid blood 
concentrations and a reduction in BMI and body weight.  In addition, adiponectin could possibly 
be the molecular link between obesity, insulin resistance and could potentially serve as the 
biomarker for the metabolic syndrome 291. 
1.2.13.5 Insulin resistance 
Insulin resistance is related to diabetes, hypertension and obesity and is characterized by 
decreases in receptor concentration, kinase activity and also the phosporylation of IRS-1 and 
IRS-2, PIK activity, glucose transporter translocation and the activity of intracellular enzymes.  
In persons who suffer from T2DM the activation of the MAP kinase pathways is not diminished 
potentially leading to some of the harmful effects of chronic hyperinsulinaemia on cell 
development in the vasculature 279, 292.   
Genetic as well as acquired factors can significantly affect insulin sensitivity.  Genetic 
defects in insulin receptor is extremely rare however it can be found in syndromes such as 
leprechaunism, Rabson Mendenhall, and type A syndrome of insulin resistance.Type 2 diabetes 
is polygenetic and entails multiple gene polymorphism that encode the proteins involved in 
insulin signaling, secretion, and also its metabolism 279. 
1.2.13.6 Diabetes in the Caribbean 
Diabetes mellitus is considered one of the most prevalent diseases and a leading cause of death in 
the Caribbean region and has emerged as a major health concern.  Diabetes is characterized by 
chronic hyperglycemia, and other metabolic disorders for instance, atherosclerosis, damage to 
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target organs such as the heart, kidneys, eyes, brain, and the peripheral nerves.  Obesity seems to 
play a central role in the development of diabetes and other co-morbid conditions such as 
hypertension and dyslipidemia.  Despite the growing concern regarding diabetes in the 
Caribbean there are still many undiagnosed individuals in that region 187. 
Diabetes mellitus has been shown to be associated with increasing age up to 
approximately the 6th decade and then eventually leveling off.  A denoted reason for this 
increased prevalence in diabetes mellitus is the aging population in the Caribbean. For example, 
amongst Barbadian Blacks diabetes was shown to be positively associated with increased age, 
family history of diabetes, central obesity and a body mass index E:(Q>U6 2187, 293.   
1.2.13.7 Economic burden of diabetes 
NIDDM causes economic burden to many societies especially bi-ethnic Caribbean countries 
such as Trinidad and Tobago 294-296.  This increase in diabetes in the Caribbean seems to be 
driven by changes in living conditions.  For example, diets in the Caribbean have become more 
like westernized countries high in fat, sugars and low in dietary fibers.  Sedentary lifestyle, and 
labor saving devices have also increased the likelihood of individuals developing diabetes 297 .   
1.2.13.8 Under report of diabetes in the Caribbean 
Diabetes in the Caribbean has a high rate of being under-reported.  For instance, in a study of the 
national death certificates in Jamaica, revealed that there was a 30% under-recognition of 
diabetes 298.  In Spanish Town, Jamaica the prevalence of diabetes in persons with an average 
age of 47 years was 9.8% for men and 15.7% in women with an overall prevalence of 13.4% 297.  
In Trinidad and Tobago, the prevalence among Indo-Trinidadian men and women 35-69 years of 
age increased from 11.6% and 18.9% in 1961-62 to 19.5% and 21.6% in 1977.  Among Afro-
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Trinidadians the rates were 2.5% to 8.2% among men and 5.4% to 14.8% amongst women 294, 
299.  This epidemic of diabetes mellitus is expected to continue with a 35% increase in the 
prevalence from 1995 until 2025 which will be accompanied by growth in population size, which 
will be largest in developing countries 300.  
In Trinidad and Tobago type 2 diabetes accounts for approximately 13.6% of hospital 
admissions and cost the government an estimated US$ 1.6 million dollars 301.  It is well 
established that abdominal obesity is associated with insulin resistance and is highly predictive 
of the development of type 2 diabetes and other cardiovascular diseases 302.  In the Caribbean, 
there is also a gender dimorphism in which females have a higher prevalence of diabetes and 
obesity.  The influence of lifestyle factors on prevalent diabetes has been succinctly 
demonstrated by the International Collaborative Study on Hypertension in Blacks in which a 
gradient of prevalent diabetes cases was delineated ranging from 2.0% in West Africa to 9.0% in 
the Caribbean and 11% in African Americans 303.  
In this region of the world many of the studies on the prevalence of diabetes in the 
Caribbean were conducted more than 30 years ago 299, 304-306 and since then there have been 
changes in diagnostic criteria which has significantly limited the ability to compare those data to 
current data.  However, Poon-King et al. conducted a prevalence study in approximately 2400 
individuals in July 1961 and found that rates of diabetes were 2.4% in East Indian Trinidadians 
and 1.4% in African descent Trinidadians 299.  There are no new studies addressing the 
differences in rates of diabetes in blacks and Indians residing in Trinidad today. 
1.2.14 Hypertension 
A small percentage of patients have as the main cause of their hypertension renal or adrenal 
disease approximately 2%-5%.  However, in the remaining population there is no single 
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identifiable cause for this disease called essential hypertension.  There are a number of 
physiologic processes involved in the maintenance of normal blood pressure and their 
disturbance is possibly a key role in the development of essential hypertension.  It is also quite 
possible that there are a number of inter-related factors involved in the etiology of hypertension.  
Some of the more intensely studied factors are:  salt-intake, obesity, insulin resistance, the 
rennin-angiotensin system, and sympathetic nervous system307. 
1.2.14.1 Definition of hypertension 
Hypertension is defined as the “consistent elevation of the systemic arterial blood pressure”.  
Individuals are usually diagnosed as having hypertension after an average of approximately two 
or more diastolic blood pressure measurements of 90 mm Hg or higher on consecutive visits or 
when the average systolic blood pressure measurements on consecutive visits is 140 mm Hg or 
greater 245.  
Hypertension is typically caused by an increase in cardiac output, peripheral resistance or 
a combination of both.  Increases in cardiac output can be caused by any condition that could 
increase the heart rate or stroke volume.  On the other hand, peripheral resistance is caused by 
any condition that increases the viscosity of the blood or decreases vessel diameters for instance 
arteriolar diameter. Individuals who suffer from hypertension can have a combined systolic and 
diastolic hypertension or some individuals might have isolated systolic hypertension.  Usually 
most cases of combined systolic and diastolic have no clearly delineated causes and so are 
termed primary hypertension.  Primary hypertension is also called essential hypertension or 
idiopathic hypertension 308.  Hypertension of unknown origin is termed essential hypertension.  
This type of hypertension is treatable but not curable and there is a strong hereditary component 
309. 
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1.2.14.2 Characteristics of severe hypertension 
) MAP is increased by 40-60% 
) In severe stages renal blood flow is decreased by one half of normal 
) Blood flow through the kidneys is increased twofold to four fold 
) CO is normal 
) The kidneys do not excrete adequate salt and water unless the arterial pressure is high 
309. 
Secondary hypertension is usually caused by altered hemodynamics related to the 
primary disease such as arteriosclerosis.  Secondary hypertension accounts for approximately 5% 
to 8% of cases.Isolated systolic hypertension is defined as elevated systolic blood pressure 
accompanied by normal diastolic blood pressure defined as <90 mm Hg.  Isolated systolic blood 
pressure is characterized by increased cardiac output or rigidity of the aorta or both 310.   
1.2.14.3 Obesity and Hypertension 
The relationship between hypertension and obesity is well documented.  Individuals with larger 
body masses seem to have higher blood pressure and also higher rates of hypertension 311, 312.  
The most significant modifiable risk factors for hypertension are overweight and obesity 
accounting for nearly 66% of the risk in many populations 313. For instance, in the Nurses Health 
Study (NHS), data showed that BMI values at 18 years and also midlife were positively 
correlated with hypertension.  In this study, there was a significant association between long-
term weight loss after the age of 18 years and a decreased risk of hypertension while weight gain 
after 18 years significantly increased this risk. This association continued to remain significant 
following the adjustments for current BMI which implied that BMI and history of weight 
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changes are independent predictors of hypertension 314.  In the Framingham Study Moore et 
al.,315 reported that when modest amounts of weight loss were sustained over an extended period  
of time it was associated with a 22% to 26% reduced risk of hypertension.   
A variety of mechanisms have been postulated to help explain the relationship between obesity 
and hypertension.  One such mechanism states that obesity and overweight causes renal 
structural changes that lead to tubular re-absorption and also sodium retention 156, 316.This further 
causes an elevation in arterial pressure which damages nephron function causing obesity, 
hypertension and renal damage 156. 
1.2.14.4 Environment 
Environmental factors can also play an important role in hypertension.  Environmental factors 
that are implicated in the development of hypertension are salt intake, obesity, occupation, 
alcohol intake, family size and crowding.  These listed factors are important for the development 
of high blood pressure with increasing age in the more affluent societies compared to the decline 
in blood pressure noticed in the less affluent societies 317. The environmental factor of all the 
above listed that has received the most attention is salt sensitivity.  The cause of salt sensitivity in 
individuals is dependent on a number of factors namely: primary aldosterism, bilateral renal 
artery stenosis, renal parenchymal disease and low-renin essential hypertension which accounts 
for approximately half of the patients317. 
1.2.14.5 Nutrition 
Lifestyle factors can also affect the development of hypertension.  These factors include: 
excessive caloric consumption, excessive sodium consumption, excessive alcohol intake, 
inadequate potassium, inadequate calcium intake mostly in elderly African Americans, 
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inadequate physical activity, poor fitness level, and cigarette smoking 317.  Diet related diseases 
and conditions related to hypertension include: obesity/overweight, diabetes mellitus, and 
dyslipidemias.  In addition, adverse health outcomes that are associated with uncontrolled or 
poorly controlled hypertension are: cardiovascular disease, coronary heart disease, left 
ventricular hypertrophy, angina, myocardial infarction, congestive heart failure, nephropathy, 
cerebrovascular disease, transient ischemic attacks, stroke (CVA), peripheral artery disease 
(PAD), and retinopathy 317. 
1.2.14.6 Pathophysiology of hypertension 
Although the exact pathogenesis of primary hypertension remains to be elucidated, several 
hypotheses have been proposed.  These include (1) increased blood volume, (2) inappropriate 
autoregulation, (3) overstimulation of sympathetic neural fibers in the heart and vessels, (4) 
water and sodium retention by the kidneys, and (5) hormonal inhibition of sodium-potassium 
transportation to kidneys and blood vessels. Researchers hypothesize that any of these 
mechanisms or a combination of more than one might be at work in the pathogenesis of primary 
hypertension 310.   
Chronic hypertension can cause changes in the walls of the systemic blood vessels.  
Extended vasoconstriction along with high pressures within these vessels especially in the 
arteries and arterioles can cause the vessels to thicken and toughen to handle stress. These 
arterial smooth muscles further undergo cellular enlargement (hypertrophy) and cellular 
proliferation (hyperplasia).  Later the tunica intima and the tunica media develop fibromuscular 
thickening that cause significant narrowing of the lumina. The injury of these vessels promotes 
biochemical mediators of inflammation that increase the permeability of the vascular 
endothelium.With the increased permeability humoral substances are absorbed into the vessel 
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walls causing further thickening and smooth muscle contraction 310.  The contraction of the 
smooth muscle cells is thought to be caused by a rise in the intracellular calcium concentration, 
which could possibly explain the vasodilatory effect of certain drugs that block calcium 
channels.  Furthermore, this smooth muscle constriction of the arteriolar vessels causes structural 
changes leading to an irreversible rise in peripheral resistance 307. 
In addition, it has been hypothesized that in the early stages of hypertension the 
peripheral resistance is not raised and that the elevation of the blood pressure is induced by the 
elevated cardiac output, which is associated with sympathetic over activity.  This rise in 
peripheral arteriolar resistance could be considered a compensatory mechanism to prevent a raise 
in pressure being transmitted to the capillary bed where it could affect cell homeostasis 307. 
1.2.14.7 Reninangiotensin system 
The rennin angiotensin system is considered to be one of the most important of the endocrine 
system that regulates blood pressure.  Renin is secreted by the juxtaglomerular system of the 
kidneys in reaction to glomerularunderperfusion or decreased sodium intake.  Renin is also 
emitted in response to stimulation by the sympathetic nervous system 307.  
Renin acts on the rennin substrate angiotensinogen converting it to angiotensin I, which is 
rapidly converted in the lungs by angiotensin converting enzyme to angiotensin II.  Angiotensin 
is a vasoconstrictor and causes a rise in blood pressure.  It also stimulates the adrenal gland to 
release aldosterone which cause a further rise in blood pressure associated with sodium and 
water retention 307. 
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1.2.14.8 Autonomic nervous system 
The stimulation ofthe sympathetic nervous system can induce constriction and dilatation of the 
arteriolar.  The autonomic nervous system plays an important role in the management of blood 
pressure. The autonomic nervous system also regulates temporary variations in blood pressure 
that might be related to increases in stress levels and physical activity.  It is postulated that 
hypertension is associated with the interaction of the autonomic nervous system, the rennin-
angiotensin system and other factors for instance, sodium and circulating volume 307.   
1.2.14.9 Cardiac output and peripheral resistance 
The ability to maintain a normal blood pressure is dependent on a balance in cardiac output and 
peripheral vascular resistance.  Peripheral resistance is dependent on the walls of the small 
arterioles, which are comprised of smooth muscle cells.  The continued constriction of the 
smooth muscle can cause structural changes in addition to the thickening of the arteriolar vessel 
walls possibly mediated by angiotensin leading to an irreversible rise in peripheral resistance.  It 
has been hypothesized that in the very early stages of hypertension elevation of blood pressure is 
caused by elevated cardiac output that is related to sympathetic over-activity307. 
1.2.14.10 Sympathetic over-activity 
Individuals who were obese had higher serum catecholamine and muscle sympathetic nervous 
activity (MSNA) than lean individuals.MSNA was significantly higher in persons with central 
obesity compared to individuals with peripheral obesity 318. High resting heart rates and 
baroreflex dysfunction has been cited in the development of hypertension in the metabolic 
syndrome 319-321.   
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Individuals who are obese have an activated rennin angiotensin system, which can bring 
on hypertension 322.  This angiotensin system and the sympathetic nervous system are linked by 
positive feedback 323.  Possible agents involved in the stimulation of sympathetic nervous action 
in the metabolic syndrome are: elevated leptin, insulin resistance, and non-esterfied fatty acids 
(NEFA) 324F##WXBJ#0$-8.8#42++&#70.8890.M#=.$0/#0$/.M#$%&#VS-adrenoceptor vasoreactivity but also 
reduces baroreflex sensitivity, endothelium-dependent vasodilatation, and vascular compliance 
325.   
Second, insulin resistance raises plasma leptin levels and it has been delineated that leptin 
increases sympathetic nervous activity suggesting that leptin-dependent sympathetic nervous 
activation could contribute to obesity associated hypertension 326.  There is also data suggesting 
that the metabolic syndrome is related to markers of adrenergic overdrive 327. 
1.2.14.11 Oxidative stress and endothelial dysfunction 
In animal studies involving rats with the metabolic syndrome, following the consumption of high 
fat and refined sugars these animals had hypertension that was related to oxidative stress, nitric 
oxide inactivation, down regulation of nitric oxide synthaseisoforms, and endothelial nitric oxide 
synthase activator 328.  This indicated that oxidative stress and endothelial dysfunction could be 
related to the development of hypertension in the metabolic syndrome.  Moreover, current 
evidence indicate that oxidative stress, which is elevated in metabolic syndrome is related to 
sodium retention and sensitivity 329. 
In non-diabetics lipid peroxidation was correlated with body mass index and waist 
circumference suggesting that the accumulation of adipose tissue is correlated to oxidative stress 
in individuals 330.  Likewise, cross-sectional data from the Framingham offspring Study, showed 
that systemic oxidative stress is related with insulin resistance 331.  
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Insulin resistance causes an impairment in phosphatidylinositol 3-kinase (PI3K) which 
may cause an imbalance in the production of nitric oxide and the secretion of endothelin-1 
further leading to endothelial dysfunction 332.  Epidemiological studies show a reciprocal 
relationship between endothelial dysfunction leading to the development of hypertension and 
insulin resistance 332. 
1.2.14.12 Inflammatory mediators 
Abnormalities in the inflammatory markers have been reported as being related to the 
development of hypertension.  For instance, in the Women Health Study, a positive relationship 
existed between elevated serum CRP levels and the development of hypertension 333.  A strong 
association between inflammation, hypertension, and the metabolic syndrome was likewise 
proposed by Grundy SM 334. 
Second, TNF-V#-8#*+%8-&.0.&#/+#72$5#$#Q.5#role in the pathophysiology of hypertension 
and the metabolic syndrome.  TNF-V# $*/-1$/.8# /=.# 70+&9*/-+%# +,# .%&+/=.2-%-1 and 
angiotensinogen335, 336 and, TNF-V#>.%.#2+*98#-8#=57+/=.8-Y.&#/+#72$5#$#0+2.#-%#-%892-%#0.8-8/ance 
mediated hypertension 337.  Serum TNF-V# =$8# 4..%# 8=+G%# /+# 4.# 7+8-/-1.25# 0.2$/.&# /+# 858/+2-*#
blood pressure and insulin resistance 338 and elevated  TNF-V# 2.1.28# =$8# 4..%# &./.*/.&# -%#
monocytes from individuals with hypertension 339. 
Furthermore, studies have also shown that blood pressure is a significant and independent 
predictor of IL-6 levels in women 340  and that IL-6 stimulates the central and the sympathetic 
nervous system which could potentially cause hypertension 341, 342. In women who were given 
IL-6 an elevation in heart rate, and serum norepinephrine levels were observed 343.  IL-6 causes 
an increase in plasma angiotensinogen and angiotensin II leading to the development of 
hypertension 344. 
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1.2.15 Hypertension prevalence in Afro-Caribbeans 
In a cohort of individuals from the Barbados Eye Study, more than half of the participants had 
hypertension at baseline with approximately one in two men and three in five women being 
affected by this disease.In this cohort hypertension increased with age and was similar for men 
and women between the age of 40-49; however, age specific rates were higher among women at 
older ages 345.  Age specific hypertension increased from 32.7% in men and 34.0% in women age 
40-49 to 63.4% in men and 85.5% in women at age 80 and above with an overall prevalence in 
this population of 55.4 percent.  Additionally, in this study hypertension awareness, treatment 
and control rates were 62.5, 53.8 and 18.5% respectively 345.   
Bobb-Liverpool et al.,346 reported that, in Jamaica hypertensive women had inadequate 
knowledge of hypertension, and poor compliance with JNCVI guidelines (Joint National 
Committee on Prevention, Detection and Evaluation and Treatment of High Blood Pressure).In 
this population, it was recommended that to improve patient compliance, counseling/education 
on diet, exercise, medication, and weight management be provided.In Trinidad and Tobago a 
study that evaluated health behavior patterns of chronic disease patients in relation to diet, 
weight control, and medication, determined that health professionals did not provide patients 
with the sufficient knowledge to adopt healthy lifestyles to prevent disease347.  
Following age standardization similarly high rates of hypertension were found in other 
countries of the African Diaspora that mirror levels of western acculturation.  In the French 
speaking country of the Antilles called Guadeloupe, the prevalence of hypertension was 24.7% 
for men and 22.1% for women.  In this population the major contributing factor was once again 
obesity especially in the disadvantaged cohort that was evaluated 348.  
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Similarly findings were confirmed from a combined study of the Birmingham factory 
screen, Birmingham INTERSALT volunteers and four West-Midlands churches.  In this cohort 
of N=2853, Afro-Caribbean’s had a significantly higher systolic blood pressure with higher 
diastolic blood pressure in the Afro-Caribbean women. Even following the adjustment of age, 
BMI, smoking, and alcohol intake the odds ratios and 95% confidence interval for being 
hypertensive were 1.56 (1.14 to 2.13; P=0.005) and 2.40 (1.51 to 3.81; P=0.0002) in Afro-
Caribbean men and women respectively 349. 
1.2.16 Prevalence of hypertension in Trinidad 
In Trinidad the incidence of hypertension and non-insulin dependent diabetes mellitus in African 
and Indian populations residing in St. James did not differ significantly according to ethnicity.  
In a cohort comprised of 2,491 men and women age 35 to 69 years of age, incidence rates of 
hypertension ranged between 33 and 41 per 1000 persons in men and 27 and 32 per 1000 in 
person years in women 350. 
Nichols et al.,10reported that blood pressure in Tobagonian adolescent population was 
found to be significantly higher than children residing in the U.S.A using US reference level cut 
points for systolic and diastolic blood pressure.  The prevalence of elevated diastolic blood 
pressure was almost twice the expected levels using US cut points. The results of the Tobagonian 
study indicated that Tobagonian adolescents were heavier than adolescence residing in the 
United States, United Kingdom and Jamaica.  Blood pressure in this study was associated with a 
family history of hypertension and being overweight. 
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2.0  PUBLIC HEALTH SIGNIFICANCE 
Prostate cancer is one of the most common malignancies and the second leading cause of cancer 
related deaths in the United States and other countries 351 .  African American men have been 
found to have the highest incidence rates for prostate cancer of all racial and ethnic groups 351.  
High rates of prostate cancer have also been observed in Afro-Tobgonian men 35, 42.  Screening 
detected prostate cancer prevalence rates were 4.9% for individuals aged 50-55, 7.7% for 
individuals ages 55-59; and 13.3% for individuals aged 60-64 years 35.  Even though the reasons 
for the large disparity in prostate cancer risk are not fully understood, one possible explanation is 
androgen levels351.  A common treatment for prostate cancer is androgen deprivation therapy 
(ADT) which reduces the levels of androgen in the body but also has many side effects352.  
Consequently, prostate cancer is a major public health concern and especially in persons of 
African ancestry.  Further studies are needed to investigate the effects of treatments for prostate 
cancer such as ADT in at risk populations. 
Obesity is also a major public health concern.  Individuals who are considered 
minority/non-white are more prone to increases in weight and its associated complications353.  
World wide there are approximately a billion adults that are considered overweight and 300 
million that are considered obese353.  In the United States the prevalence of obesity in African 
Americans between 2003 and 2004 was 76.1%354.  According to a 2003-2004 health survey that 
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was conducted in England Black Caribbean men had the highest prevalence rates of obesity 
compared to Bangladeshi, Chinese, Pakistani, Black African and Indian men355.   
Hypertension is also a disease that affects people of African descent and is of major 
public health concern.  In the United States the prevalence of hypertension is highest amongst 
black Americans356.  Individuals of African descent appear to develop high blood pressure much 
earlier in life, have higher average blood pressures and experience poorer outcomes357.   
Obesity and hypertension are multi-factorial in origin and the development of these 
diseases requires interplay between genes and the environment356, 358, 359.  Therefore, to elucidate 
the relationship between high blood pressure, obesity and candidate genes, we propose to 
investigate the association between ADRB2, blood pressure, and obesity in Afro-Tobagonian 
men.  In addition, we also propose to investigate the association between AR CAG and obesity in 
Afro-Tobagonian men.  We hope that these studies will provide important clues into the etiology 
of aforementioned diseases.  Moreover, we hope that these studies will increase our knowledge 
in understanding the role race/ethnicity plays as a risk factor, the identification of treatments that 
target specific populations, and the selection of appropriate therapies. 
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3.0  SYNTHESIS STATEMENT 
This paper attempts to elucidate complex phenotypes such as body weight and blood pressure in 
a cohort of Afro-Caribbean men who reside on the island of Tobago.  Research on obesity and 
blood pressure has revealed that genetics, diet, environment, behavior, and social norms play 
important roles in disease etiology.  The multi-factorial nature of obesity and blood pressure and 
the involvement of many genes have made the search for candidate genes exceedingly difficult.  
These papers seek to further understand the role ADRB2 and AR CAG repeats plays in the 
development of obesity related phenotypes and blood pressure. 
A common treatment for prostate cancer (Prostate cancer) is androgen deprivation 
therapy (ADT). ADT is typically considered the treatment of choice for metastatic prostate 
cancer.  Androgens are important for physiologic activity of myriad bodily functions.  However, 
ADT administration has several deleterious side effects one of which is altered body 
composition.  This paper also investigates the effect of ADT administration in Prostate cancer 
individuals on the rate of change of percent total body fat (DEXA) from baseline to follow-up in 
Afro-Tobagonian men.  We hope that these studies will strength our understanding of the 
association between genes and our primary outcomes and secondly in explaining whether the 
rate of change of percent total body fat increases or decreases with ADT exposure. 
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4.1 ABSTRACT 
Objective: <2$88-*# /-889.# .,,.*/8# +,# L:# $&0.%.0>-*# 0.*.7/+0# $*/-1$/-+%# -%*29&.# 8Q.2./$2# 698*2.#
glycogenolysis and vascular smooth muscle relaxation, factors relevant to obesity and 
hypertension, respectively. In a population-based study, we examined two common amino acid 
8948/-/9/-+%8# -%# /=.#L:#$&0.%.0>-*# 0.*.7/+0#>.%.# ?JIZA:3# -%# 0.2$/-+%# /+#4+&5#*+67+8-/-+%#$%&#
blood pressure. 
Design and subjects: Cross-sectional analysis of 1965 African descent men living in Tobago and 
participating in a prostate cancer screening study. 
Measurements: Body mass index (BMI), waist circumference, blood pressure, dual energy X-ray 
absorptiometry (DEXA) body composition, and ADRB2 (Arg16Gly; Gln27Glu) genotype. 
Results: Twenty-five percent were obese (BMI E# CT# Q>U6:3# $%&# (T)# =57.0/.%8-1.F# JIZA:#
Arg16Gly and Gln27Glu alleles were in linkage disequilibrium (D[\TF']3F# JIZA:# S]O25 -
containing and 27Glu-containing genotypes were equally frequent in low, medium, and high 
tertiles of percentage body fat mass (16Gly-containing genotypes: 73.2%, 74.4%, 75.1%, 
ptrend=0.45; 27Glu-containing genotypes: 27.8%, 24.2%, 26.4%, ptrend=0.58) and in normal 
blood pressure, pre-hypertensive, and hypertensive men (16Gly-containing genotypes: 73.6%, 
72.5%, 74.6%, ptrend=0.55; 27Glu-containing genotypes: 26.1%, 24.6%, 27.1%, ptrend=0.51). 
Conclusion: In a high obesity and high hypertension risk population with ancestry in common 
with African-Americans, genetic variation defined by two common ADRB2 amino acid 
substitutions was not associated with body composition or hypertension. 
 
^.5#G+0&8;#J,0-*$%#$%*.8/05M#$&0.%.0>-*#L:#0.*.7/+0M#>.%./-*#7+256+07=-86M#4+&5#*+6position 
blood pressure, hypertension 
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4.2 INTRODUCTION 
Interacting with diet and physical activity, genetic factors contribute to obesity and 
hypertension.[1-3] Frequently studied candidate genes include the leptin,[4] catecholamine,[5] 
and peroxisomeproliferator-activated receptors [6] and genes in the renin-angiotensin system.[7] 
K/-692$/-%>#L#$&0.%.0>-*#0.*.7/+0#,9%*/-+%#70+6+/.8#2-7+258-8#-%#,$/#*.228F_:M#`a#@=.#L:#$&0.%.0>-*#
0.*.7/+0#>.%.# ?JIZA:3#$//0$*/8# -%/.0.8/#4.*$98.#*$/.*=+2$6-%.#$*/-1$/-+%#+,# /=.#L2 adrenergic 
receptor regulates skeletal muscle glycogenolysis and vascular smooth muscle relaxation.[9] The 
ADRB2 single nucleotide polymorphisms most often studied in human populations substitute 
glycine for arginine at codon 16 (Arg16Gly) and glutamic acid for glutamine at codon 27 
(Gln27Glu).[10] 
Despite numerous published studies, the connection, if any, between ADRB2 Arg16Gly 
or Gln27Glu genotype and metabolic phenotypes, including obesity and hypertension, is 
tentative. Results from early recombinant cell culture experiments,[11] for example, launched a 
long standing hypothesis asserting that the ADRB2 16Gly variant promoted obesity and 
hypertension by causing receptor down regulation and physiologic desensitization in response to 
chronic agonist stimulation.[12] However, subsequent human experiments showed agonist-
induced desensitization only in persons with the ADRB2 16Arg variant.[12-14] A 2008 meta-
analysis examined obesity risk in relation to ADRB2 codon 16 variation (13 studies with 6825 
subjects) and in relation to ADRB2 codon 27 variation (28 studies with 14,450 subjects).[10] 
Random effects meta-regression analysis showed statistically insignificant obesity risks in 
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relation to 16Arg-containing genotype (odds ratio 1.02, 95% confidence interval 0.89-1.18) and 
in relation to 27Glu-containing genotype (odds ratio 1.11, 95% confidence interval 0.98-1.27). 
However, meta-analysis restricted to Asian (7 studies with 3575 subjects), Pacific Island (1 study 
with 1020 subjects), and native South American populations (1 study with 149 subjects) showed 
statistically significant association between 27Glu-containing genotype and obesity (odds ratio 
1.46, 95% confidence interval 1.02-2.10). One study [15] with African-American subjects, but 
not a second,[16] showed association between obesity measures and ADRB2 genotype. 
We defined a large population on the Caribbean island of Tobago with ancestry in 
common with African-Americans, determined ADRB2 Arg16Gly and Gln27Glu genotypes, 
measured blood pressure, and used dual energy X-ray absorptiometry (DEXA) to estimate body 
composition. Analyses examined ADRB2 genotypes in relation to body composition and 
hypertension. 
4.3 METHODS AND MATERIAL 
Between September 1997 and September 2007, the Tobago Prostate Study used public service 
announcements, flyers, local health care workers, and word of mouth to solicit 40-79 year-old 
men in Tobago for participation in a study of periodic prostate cancer screening.[17] The study 
excluded non-ambulatory, terminally ill, or cognitively impaired men. Participants signed written 
informed consent. The Institutional Review Boards of the University of Pittsburgh and Tobago 
Division of Health and Social Services approved the research protocol. 
The Tobago Prostate Study enrolled 3837 men. Standardized entry questionnaires 
provided demographic and basic cancer risk factor information. To support studies of obesity, 
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hypertension, diabetes, and musculoskeletal health, men enrolling or returning after January 
2004, also completed a detailed standardized staff-administered health history questionnaire. We 
defined, for the current analysis, a race-eligible study group that consisted of 3452 (90.0% of 
3837) men who reported having at least three grandparents of African descent. 
Procedures included periodic musculoskeletal tests (DEXA and/or quantitative computed 
tomography) and, for the subset of men who completed the health history questionnaire and 
accepted musculoskeletal testing, genetic tests. Information from DEXA was available for 2850 
(82.6%) and health history questionnaires for 2259 (65.4%) of 3452 race-eligible men and 
ADRB2 Arg16Gly and/or Gln27Glu genotypes for 1960 of 2133 (91.9%) race-eligible men with 
both health history questionnaires and DEXA. Data analyses included 1965 (1960 with and 5 
without DEXA) race-eligible ADRB2 genotyped men with health history questionnaires. When 
compared against the group of men not available for the health history questionnaire (n=1193) or 
not otherwise genotyped (n=294), the 1965 men included in analyses enrolled at younger age 
(median 52 vs. 56 years, p(Wilcoxon) < 0.0001). Genotyped and non-genotyped race-eligible 
men available for the health questionnaire had statistically similar body mass index (BMI), waist 
circumference, hypertension prevalence, and body composition (percent body fat). 
ADRB2 Arg16Gly (rs1042713) and Gln27Glu (rs1042714) genotype determinations used 
a TaqMan allelic discrimination assay performed on an Applied Biosystems (Foster City, CA) 
7900HT Fast Real-Time PCR System. Call rates for the ADRB2 Arg16Gly and Gln27Glu 
polymorphisms were 97.0% and 94.5%, respectively. ADRB2 Arg16Gly, Gln27Glu, and both 
Arg16Gly and Gln27Glu genotypes were available for 1856 (94.5%), 1871 (95.2%), and 1762 
(89.7%) men included in data analyses, respectively. Genotype distributions for ADRB2 
Arg16Gly and Gln27Glu satisfied Hardy-Weinberg equilibrium conditions (p>0.05). Allele 
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frequencies (16Gly 49.6%, standard error 0.8% and 27Glu 14.1%, standard error 0.6%) 
estimated for the 1965 men included in data analyses agreed with values reported by the 
International HapMap Project (www.hapmap.org) for the Yoruba population (50.0% and 17.5%, 
respectively). ADRB2 Arg16Gly and Gln27Glu alleles were in linkage disequilibrium (D[\TF']3F  
4.3.1 Outcome measurements 
Outcome measurements included height (measured without shoes to the nearest 0.1 cm on a 
wall-mounted stadiometer), weight (measured without shoes to the nearest 0.1 kg on a balance 
beam scale), BMI (calculated as weight in kg divided by height in meters-squared), and waist 
circumference (measured in cm at the umbilicus with an inelastic tape measure). Percent body fat 
was acquired on a Hologic QDR 4500W DEXA operated in array beam mode and analyzed with 
QDR software version 8.26a (Hologic Inc. Bedford, MA). After seating and resting subjects for 5 
minutes, technicians selected an appropriate cuff size and used an automated OMRON 
HEM705CP sphygmomanometer (Omron Healthcare, Inc., Vernon Hills, IL) to obtain three 
consecutive blood pressure measurements. 
4.3.2 Statistical analysis 
Using the second and third measurements, if available, or any two available measurements, 
otherwise, analyses calculated average values for systolic (SBP) and diastolic blood pressure 
(DBP). Using these measurements, we classified subjects into three mutually exclusive 
hypertension categories, hypertension (SBP > 140 mmHg or DBP > 90 mmHg or current 
antihypertensive medication use), pre-hypertension (SBP 120-139 mmHg or DBP 80-89 mmHg 
and current antihypertensive medication nonuse), and normal (SBP < 120 mmHg and DBP < 80 
mmHg and current antihypertensive medication nonuse). Sixty-six (3.3%) men were not 
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classified because of missing blood pressure measurements (n=8) and/or missing or inconsistent 
self-reports of antihypertensive medication use (n=64). BMI classification used World Health 
Organization cutpoints (underweight <18.5 kg/m2, normal weight 18.5- 24.9 kg/m2, overweight 
25-29.9 kg/m2, and obese ECT#Q>U6:3F 
Statistical analyses (SAS 9.2; SAS Institute Inc., Cary, NC) used conventional methods 
(chi-square or Fisher exact tests for discrete data and t-tests, ANOVA, or Wilcoxon rank-sum 
tests for continuous data) to evaluate the significance of group differences. Haplotype-based 
analyses used the EM algorithm implemented in SAS Genetics (PROC HAPLOTYPE) to 
estimate group-level haplotype frequencies and to generate subject-level haplotype probability 
weights.1
4.4 RESULTS 
  We then used traditional linear models (implemented in SAS PROC GENMOD with 
normal probability distribution and identity link function) to estimate independent associations 
between the haplotype probability weights and continuous outcomes (BMI and total body 
percent body fat) and logistic regression (implemented in SAS PROC LOGISTIC) to estimate 
independent associations between the haplotype probability weights and binary outcomes 
(hypertension or pre-hypertension vs. normal blood pressure). 
Study men were mean age 58.9 years (standard deviation (SD) 10.4 years). Over half (50.4%) 
were hypertensive, 32.5% pre-hypertensive, 44.1% overweight, and 25.5% obese. One in 6 
(16.5%) self-reported a physician diagnosis of diabetes. 
                                                 
1http://support.sas.com/documentation/cdl/en/geneug/59659/HTML/default/geneug_haplotype_sect021.htm 
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Genotype frequencies were 25.9% Arg/Arg, 49.1% Arg/Gly, and 25.0% Gly/Gly at 
codon 16 (n=1856) and 74.0% Gln/Gln, 23.8% Gln/Glu, and 2.2% Glu/Gly at codon 27 
(n=1871). The prevalence of obesity (BMI ECT# Q>U6:3# &-&# %+/# 1$05# $**+0&-%># /+# >.%+/57.#
(27.3% of 480, 24.6% of 908, 25.2% of 465 men with the codon 16 Arg/Arg, Arg/Gly, and 
Gly/Gly genotype, p=0.5331, and 25.9% of 1382, 26.1% of 445, and 24.4% of 41 men with the 
codon 27 Gln/Gln, Gln/Glu, and Glu/Glu genotype, p= 0.9728). Height, weight, and waist 
circumference were slightly higher in men with a 16Arg allele (Table 4-1). Otherwise, weight, 
waist circumference, BMI, and percent body fat were unrelated to ADRB2 genotype (Table 4-1). 
In the obese subset, body measurements did not vary in any systematic or meaningful way with 
respect to ADRB2 genotype (Table 4-1). 
ADRB2 16Gly-containing and 27Glu-containing genotypes were equally frequent in low, 
medium, and high tertiles of percent body fat (Table 4-2; 16Gly-containing genotypes: 73.2%, 
74.4%, 75.1%, ptrend=0.45; 27Glu-containing genotypes: 27.8%, 24.2%, 26.4%, ptrend=0.58) 
and in normal blood pressure, pre-hypertensive, and hypertensive men (Table 4-3; 16Gly-
containing genotypes: 73.6%, 72.5%, 74.6%, ptrend=0.55; 27Glu-containing genotypes: 26.1%, 
24.6%, 27.1%, ptrend=0.51). In men not taking antihypertensive medication, systolic, diastolic, 
and mean arterial blood pressure values were unrelated to ADRB2 genotype (data not shown). 
Estimated ADRB2 Arg16Gly Gln27Glu haplotype frequencies were Arg-Gln 50.0% 
(standard error 0.8%), Gly-Gln 35.9% (standard error 0.8%), Gly-Glu 13.8% (standard error 
0.6%), and Arg-Glu 0.3% (standard error 0.1%). The Figure 4-1 uses box plots to summarize 
BMI and percent body fat distributions in men classified according to most probable haplotype 
combination. In linear models, the less common Gly-Gln and Gly-Gluhaplotypes associated with 
lower BMI and lower percent body fat (Table 4-4). In obese men, these haplotypes associated 
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with higher percent body fat and lower waist circumference (Table 4-4). However, none of these 
associations, including the apparent interaction between haplotype and obesity grouping (data 
not shown), was statistically significant. Finally, logistic regression did not show statistically 
significant ADRB2 haplotype associations with either pre-hypertension or hypertension (data not 
shown). 
4.5 DISCUSSION 
Mediating fat cell lipolysis [2, 8] and vascular smooth muscle relaxation,[9] ADRB2 gene 
variants that code for functionally altered receptors could promote weight gain or high blood 
pressure. In a study of 1965 Tobago men of African ancestry, however, we observed no 
significant body composition or blood pressure associations with the two most commonly 
studied ADRB2 gene variants. 
Different investigations have reached different conclusions about the significance of 
ADRB2 genotype in relation to obesity and related phenotypes [10, 18-20]. Variability related to 
sex may explain inconsistencies in the published literature. Some authors, including Corbalan et 
al. [21] and GonzálezSánchez et al. [22], suggest that ADRB2 genotype determines not obesity, 
but obese subtype, perhaps in only one sex group. For example, in a Spanish clinic-based study 
with 40 men and 199 women, Corbalan et al. [21] compared the ADRB2 Gln27Glu genotypes of 
subjects with either abdominal obesity (BMI >30 kg/m2 and waist-to-hip ratio >0.85) or normal 
body mass (BMI <25 kg/m2 and waist-to-hip ratio <0.85). In men, but not women, 27Glu-
containing genotypes were more frequent in the group with abdominal obesity. In a Spanish 
population-based study with 319 white men and 347 white women, GonzálezSánchez et al. [22] 
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noted a statistically non-significant trend in men (but not women) between ADRB2 Gln27Glu 
genotype and obesity prevalence (20.0% of 130, 27.7% of 155, and 29.4% of 34 men with the 
codon 27 Gln/Gln, Gln/Glu, and Glu/Glu genotype, respectively, p= 0.2572). In the obese subset, 
men with the rare Glu/Glu genotype had significantly higher mean BMI (34.1 kg/m2, n=10) than 
men with either the Gln/Glu (31.9 kg/m2, n=46, p=0.013) or Gln/Gln genotype (32.0 kg/m2, 
n=26, p=0.023). To support specific association with abdominal obesity, GonzálezSánchez et al. 
[22] noted that obese men with the rare Glu/Glu genotype also had significantly higher mean 
sagittal abdominal diameter (27.8 cm, n=10) than obese men with either the Gln/Glu (24.9 cm, 
n=46, p=0.037) or Gln/Gln genotype (24.9 cm, n=26, p=0.062). Among obese women, sagittal 
abdominal diameter was not related to ADRB2 Gln27Gly genotype. In agreement with 
GonzálezSánchez et al., we observed no statistical association between obesity prevalence and 
ADRB2 genotype. Among obese Afro-Caribbean men, BMI, waist circumference, and body fat 
values were unrelated to ADRB2 genotype (Table 4-1). Simply, our results do not support a 
relationship, specifically in obese men, between ADRB2 genotype and obesity subtype. 
Excluding persons treated for high blood lipids, high blood pressure, or diabetes, 
Meirhaeghe et al. [23] studied a population-based sample of 836 35-64 year-old urban-dwelling 
persons from northern France (419 men and 417 women, 14.2% obese overall) and observed sex-
specific associations between ADRB2 genotype and body composition. Body weight, BMI, waist 
circumference, hip circumference, and waist-to-hip ratio mean values were significantly higher 
in men with the codon 16 Arg/Arg genotype than men with either the Arg/Gly or Gly/Gly 
genotype and significantly higher in men with the codon 27 Glu/Glu genotype than men with 
either the Gln/Glu or Gln/Gln genotype. In women, differences were not statistically significant. 
Observing linkage disequilibrium between 16Arg and 27Gln, Meirhaeghe et al. [23] compared, 
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in men, body composition measures according to combined genotypes at Arg16Gly and 
Gln27Gly. With the GlyGluhaplotype serving as reference, higher body weight, BMI, and waist-
to-hip ratio associated with the ArgGlnhaplotype, not with the GlyGlnhaplotype. In Afro-
Caribbean men, body weight and waist circumference were slightly higher in men with a 16Arg 
allele (Arg/Arg or Arg/Gly genotype) than men without a 16Arg allele (Gly/Gly genotype; Table 
1). However, BMI and percent body fat did not vary according to Arg16Gly genotype. Body 
weight, waist circumference, BMI, and percent body fat were completely independent of 
Gln27Glu genotype. 
Only two studies [15, 16] to date have included a meaningful number of African-
Americans. The Insulin Resistance and Atherosclerosis (IRAS) Family Study [15] genotyped 
272 African Americans and 720 Hispanic Americans from 18 and 45 families, respectively, and 
used single-slice computed tomography to measure visceral and subcutaneous fat. Obesity 
measures associated with Gln27Glu, specifically the Glu/Glu genotype, but not with Arg16Gly 
genotype. High visceral fat area associated with the Glu/Glu genotype, even after control for 
BMI. Results for men and women and for African and Hispanic Americans were statistically 
indistinguishable. The Heritage Family Study included 274 African-Americans (31.8% obese) 
and 502 whites (19.3% obese) and used under water weighing to measure fat mass, single-slice 
computed tomography to measure visceral and subcutaneous fat, and skin calipers to measure 
skin-fold thickness[16]. In white obese (BMIECT# Q>U6:3# 894b.*/8# +%25M# /=.# c.0-/$>.# B$6-25#
Study observed lower fat mass in obese white men with 27Glu-containing genotypes and lower 
fat mass in obese white women with 16Gly-containing genotypes. In African-American subjects, 
the Heritage Family Study did not report any statistically significant cross-sectional associations 
between ADRB2 genotype and any body composition measure. 
  76 
One study of ADRB2 genotype included Afro-Caribbeans recruited from primary care 
clinics located on St. Vincent [24]. The case group included 136 patients (19.9% men) with high 
blood pressure (DBP > 95 mmHg or antihypertensive medication use) and family history of 
hypertension. The control group included 81 patients (46.9% men) with normal blood pressure 
(DBP < 85 mmHg and antihypertensive medication nonuse) and no family history of 
hypertension. The 16Gly allele was much more frequent in the case group (84.6% vs. 66.7%; 
p=0.000014). Our community-based study of 1965 Afro-Caribbean men from Tobago included 
331 and 557 persons who satisfied the St. Vincent case and control definitions. In Tobago, 16Gly 
was also more frequent in cases, 51.5% vs. 48.7%. However, the difference was not statistically 
significant (p(allele chi-square)=0.2594). In the St. Vincent study, genotype frequencies in both 
the case and control groups violated Hardy-Weinberg equilibrium. The control frequency 
(66.7%) of the putative risk allele (16Gly) in St. Vincent was high when compared against 
reference frequencies in the HapMap Yoruba (50.0%) and Tobago populations (49.5%). 
Therefore, selection bias and genotyping error plausibly explain the anomalous St. Vincent 
results. 
Our study participants volunteered for prostate cancer screening, in many instances 
survived a variable duration after study entry, and agreed to extra visits that included 
measurements, such as DEXA. Therefore, absence of meaningful association between ADRB2 
genotype and body composition could occur if these study selection factors preferentially 
excluded men with certain genotype-phenotype combinations. However, selection bias deriving 
from factors related to initial study participation can be discounted to the extent that Tobago 
Prostate Study, as a whole, enrolled a high proportion (60%) of age-eligible men (approximately 
5000) living in Tobago. To address possible survival bias, we compared the 1727 and 238 men 
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who had body composition measurements after study entry and coincident with study entry, 
respectively, and found statistically similar relationships between ADRB2 genotype and body 
composition (data not shown). Finally, study procedures captured a reasonable proportion (1965 
of 3452, 56.9%) of race-eligible Tobago Prostate Study enrollees. 
Results from some studies suggest specific ADRB2 association with regional fat 
distribution [15, 21-23]. Our primary body composition measures, BMI and DEXA-derived 
percent body fat, do not distinguish between visceral and subcutaneous fat. However, our data 
set included waist circumference, an indirect measure of central obesity. Waist circumference 
and ADRB2 genotype were statistically independent (Table 4-1). 
Finally, we evaluated only two ADRB2 genetic variants. These variants change the 
$6-%+# $*-&# 8.d9.%*.# +,# /=.# L:# $&0.%.0>-*# 0.*.7/+0# 70+/.-%F# c+G.1.0M# /=.8.# *=$%>.8# $0.# %+/#
generally believed to alter agonist binding or signal transduction [12]. The Arg16Gly and 
Gln27Glu variants may affect function secondarily, perhaps through agonist-induced receptor 
protein down regulation or linkage disequilibrium with other less common but more influential 
variants [12]. 
In a large racially homogenous population of men with black African ancestry and high 
prevalence of obesity and hypertension, single variant and haplotype-based analyses did not 
show meaningful or consistent association between ADRB2 Arg16Gly and Gln27Glu variation 
and phenotypes related to obesity and hypertension. 
  
  78 
4.6 REFERENCES 
 
1. Liu Z-q, Mo W, Huang Q, Zhou H-h. Genetic polymorphisms of human beta-adrenergic 
receptor genes and their association with obesity.Zhong Nan daXueXueBao Yi Xue Ban. 
Jun 2007;32(3):359-367. 
2. Arner P. Genetic variance and lipolysis regulation: implications for obesity. Ann Med. Nov 
2001;33(8):542-546. 
3. Marti A, Martinez-Gonzalez MA, Martinez JA. Interaction between genes and lifestyle 
factors on obesity.Proc Nutr Soc. Feb 2008;67(1):1-8. 
4. de Silva AM, Walder KR, Boyko EJ, et al. Genetic variation and obesity in Australian 
women: a prospective study. Obes Res. Dec 2001;9(12):733-740. 
5. Arner P, Hoffstedt J. Adrenoceptor genes in human obesity. J Intern Med. Jun 
1999;245(6):667-672. 
6. Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa MI. Effect of the Pro12Ala 
polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-
diabetic subjects. Diabetologia. Jul 2001;44(7):925-926. 
7. Strazzullo P, Iacone R, Iacoviello L, et al. Genetic variation in the renin-angiotensin system 
and abdominal adiposity in men: the Olivetti Prospective Heart Study.[Summary for 
patients in Ann Intern Med. 2003 Jan 7;138(1):I26; PMID: 12513065]. Ann Intern Med. 
Jan 7 2003;138(1):17-23. 
8. Large V, Hellstrom L, Reynisdottir S, et al. Human beta-2 adrenoceptor gene 
polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 
adrenoceptor function. J Clin Invest. Dec 15 1997;100(12):3005-3013. 
9. Westfall TC, Westfall DP. Chapter 6. Neurotransmission: The Autonomic and Somatic 
Motor Nervous Systems (Table 6-6). Goodman & Gilman's The Pharmacological Basis of 
Therapeutics, 11e [http://www.accessmedicine.com/content.aspx?aID=954433. Accessed 
February 19, 2010]. 
10. Jalba MS, Rhoads GG, Demissie K. Association of codon 16 and codon 27 beta 2-
adrenergic receptor gene polymorphisms with obesity: a meta-analysis. Obesity. Sep 
2008;16(9):2096-2106. 
11. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 
2-adrenergic receptor impart distinct agonist-promoted regulatory properties.[Erratum 
appears in Biochemistry 1994 Nov 29;33(47):14368]. Biochemistry. Aug 16 
1994;33(32):9414-9419. 
12. Brodde O-E. Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular 
diseases.FundamClinPharmacol. Apr 2008;22(2):107-125. 
13. Bruck H, Leineweber K, Park J, et al. Human beta2-adrenergic receptor gene haplotypes 
and venodilation in vivo. ClinPharmacolTher. Sep 2005;78(3):232-238. 
14. Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-
adrenergic receptor on agonist-mediated vascular desensitization.N Engl J Med. Oct 4 
2001;345(14):1030-1035. 
  79 
15. Lange LA, Norris JM, Langefeld CD, et al. Association of adipose tissue deposition and 
beta-2 adrenergic receptor variants: the IRAS family study. Int J Obes.May 
2005;29(5):449-457. 
16. Garenc C, Perusse L, Chagnon YC, et al. Effects of beta2-adrenergic receptor gene variants 
on adiposity: the HERITAGE Family Study. Obes Res. May 2003;11(5):612-618. 
17. Bunker CH, Patrick AL, Konety BR, et al. High prevalence of screening-detected prostate 
cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol 
Biomarkers Prev. Aug 2002;11(8):726-729. 
18. Hayakawa T, Nagai Y, Kahara T, et al. Gln27Glu and Arg16Gly polymorphisms of the 
beta2-adrenergic receptor gene are not associated with obesity in Japanese men. 
Metabolism. Sep 2000;49(9):1215-1218. 
19. Hellstrom L, Large V, Reynisdottir S, Wahrenberg H, Arner P. The different effects of a 
Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and in females.J 
Intern Med. Mar 1999;245(3):253-259. 
20. Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of 
polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, 
and diabetes mellitus. Diabetologia. Jan 1999;42(1):98-101. 
21. Corbalan MS, Marti A, Forga L, Martinez-Gonzalez MA, Martinez JA. Beta(2)-adrenergic 
receptor mutation and abdominal obesity risk: effect modification by gender and HDL-
cholesterol. Eur J Nutr.Jun 2002;41(3):114-118. 
22. Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT, et al. The glutamine 27 glutamic 
acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity 
and greater risk of impaired glucose tolerance in men but not in women: a population-based 
study in Spain. ClinEndocrinol (Oxf). Oct 2003;59(4):476-481. 
23. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. Impact of polymorphisms of the 
human beta2-adrenoceptor gene on obesity in a French population. Int J 
ObesRelatMetabDisord. Mar 2000;24(3):382-387. 
24. Kotanko P, Binder A, Tasker J, et al. Essential hypertension in African Caribbeans 
associates with a variant of the beta2-adrenoceptor. Hypertension. Oct 1997;30(4):773-776. 
 
  80 
 
Table 4-1:  Body composition measures (means ± standard deviations) according to ADRB2 genotype. 
 Arg16Gly  Gln27Glu 
Body composition measure Arg/Arg Arg/Gly Gly/Gly 
p-value 
[1]  Gln/Gln Gln/Glu Glu/Glu 
p-value 
[1] 
All men 
n [2] 477–480 905–910 461–465   1379–1383 441–446 41  
Height (cm) 175.7 ± 7.1 175.0 ± 6.9 174.5 ± 6.6 0.0175  174.8 ± 6.8 175.4 ± 7.1 175.5 ± 6.6 0.2534 
Weight (kg) 84.9 ± 15.0 84.8 ± 17.1 82.8 ± 15.6 0.0528  84.6 ± 16.2 84.7 ± 17.3 84.0 ± 14.5 0.9733 
Waist circumference (cm) 93.4 ± 12.7 93.5 ± 11.3 92.1 ± 11.3 0.0798  93.3 ± 11.6 93.1 ± 11.3 92.2 ± 8.8 0.7911 
Body mass index (BMI; kg/m2) 27.5 ± 4.4 27.7 ± 5.1 27.2 ± 4.7 0.1894  27.7 ± 4.9 27.5 ± 5.1 27.2 ± 3.9 0.6795 
Total body fat (%) [3] 20.9 ± 6.4 21.3 ± 6.3 20.7 ± 6.3 0.1963  21.2 ± 6.3 21.0 ± 6.5 21.5 ± 6.0 0.7455 
                      
Obese men (BMI !"#$"%&'(2) 
n [2] 129-131 221-223 116-117   354-358 114-116 10  
Height (cm) 174.9 ± 6.6 175.3 ± 6.2 174.0 ± 6.7 0.2235  174.6 ± 6.3 175.3 ± 7.2 177.5 ± 6.7 0.2709 
Weight (kg) 101.2 ± 12.4 104.8 ± 17.2 101.1 ± 12.8 0.0307  103.0 ± 14.7 103.8 ± 17.8 102.0 ± 8.3 0.8557 
Waist circumference (cm) 105.5 ± 9.8 106.6 ± 9.5 104.8 ± 8.2 0.2082  106.1 ± 9.6 105.9 ± 8.2 101.6 ± 4.0 0.3093 
Body mass index (BMI; kg/m2) 33.1 ± 3.1 34.1 ± 5.3 33.4 ± 3.3 0.0704  33.8 ± 4.5 33.7 ± 4.9 32.4 ± 1.5 0.6315 
Total body fat (%) [3] 25.9 ± 5.2 26.6 ± 4.8 26.1 ± 4.4 0.3392  26.3 ± 4.7 26.6 ± 5.0 25.7 ± 4.0 0.7848 
1. Statistical significance (ANOVA) of differences in mean values across genotype categories 
2. Sample numbers vary because of missing attribute data 
3. Total body (except head) fat mass expressed as a percentage of total body (except head) mass 
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Table 4-2: ADRB2 genotype and body composition. 
 Percent Total Body Fat [1]  
 
Low tertile 
N=653  
Middle tertile 
N=654  
High tertile 
N=653  
ADRB2 genotype N %   N %   N %  
Arg16Gly          
Arg/Arg 165 26.8  159 25.6  153 24.9 Pglobal=0.72 
Arg/Gly 289 46.9  307 49.4  313 51.0  
Gly/Gly 162 26.3  155 25.0  148 24.1  
Arg/Gly or 
Gly/Gly 
451 73.2  462 74.4  461 75.1 
Ptrend=0.45 
          
Gln27Glu          
Gln/Gln 439 72.2  471 75.8  469 73.6 Pglobal=0.31 
Gln/Glu 153 25.2  142 22.9  151 23.7  
Glu/Glu 16 2.6  8 1.3  17 2.7  
Gln/Glu or 
Glu/Glu 
169 27.8  150 24.2  168 26.4 
Ptrend=0.58 
1. Percent total body fat (total body (except head) fat mass expressed as a percentage of total 
body (except head) mass) -- Low tertile: 4.769-18.824; Middle tertile: 18.825-23.819; High 
tertile: 23.820-44.352 
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Table 4-3: ADRB2 genotype and hypertension. 
 
Normal blood 
pressure 
N=324  
Pre-
hypertensive 
N=617  
Hypertensive 
N=958  
ADRB2 genotype N %   N %   N %  
Arg16Gly          
Arg/Arg 81 26.4  160 27.5  229 25.4 Pglobal=0.90 
Arg/Gly 146 47.6  281 48.3  445 49.3  
Gly/Gly 80 26.1  141 24.2  229 25.4  
Arg/Gly or Gly/Gly 226 73.6  422 72.5  674 74.6 Ptrend=0.55 
          
Gln27Glu          
Gln/Gln 224 73.9  447 75.4  667 72.9 Pglobal=0.73 
Gln/Glu 75 24.8  134 22.6  228 24.9  
Glu/Glu 4 1.3  12 2.0  20 2.2  
Gln/Glu or 
Glu/Glu 
79 26.1  146 24.6  248 27.1 
Ptrend=0.51 
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Table 4-4: Estimated difference (#$%&'(%)*+%,-'./(0',0%/'1023&45%/'%6-(7%,-89-:/1/-'%80&:;20%601<00'%men 
homozygous for a specified haplotyperelative to men homozygous for the Arg-Glnhaplotype. 
Body composition 
measure 
 Gly-Gln  Gly-Glu 
n ! 95% CI p-value  ! 95% CI p-value 
BMI (kg/m2) 1962 -0.28 -0.97, 0.41 0.4261  -0.52 -1.47, 0.43 0.2828 
Total body fat % [1] 1960 -0.16 -1.04, 0.73 0.7290  -0.40 -1.62, 0.82 0.5213 
Total body fat % [1], 
in obese men 
497 0.17 -1.14, 1.48 0.7983  0.26 -1.57, 2.09 0.7815 
Waist circumference 
(cm), in obese men 
499 -0.57 -3.21, 2.08 0.6751  -2.87 -6.58, 0.83 0.1281 
1. Total body (except head) fat mass expressed as a percentage of total body (except head) mass 
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Figure 4-1: Box plots showing body mass index (BMI; upper figure) and DEXA-determined percent body fat 
(lower figure) in men sub-group according to diplotype. 
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Figure Footnote: The number (N) in each subgroup appears above the diplotype label. Analyses 
exclude six men with an ArgGluhaplotype-containing diplotype. The line segment and diamond 
symbol within each box identify the median and mean, respectively. The lower and upper 
borders of each box identify the 25th and 75th percentiles, respectively. The lower whisker 
extends to the minimum observation greater than or equal to the 25th percentile minus 1.5 times 
the inter-quartile range. The upper whisker extends to the maximum observation less than or 
equal to the 75th percentile plus 1.5 times the inter-quartile range. Open circle symbols identify 
individual observations less than the 25th percentile minus 1.5 times the inter-quartile range or 
greater than the 75th percentile plus 1.5 times the inter-quartile range. 
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5.1 ABSTRACT 
Objective:  Expansion of AR CAG repeat has been shown to lower transcriptional activity 
causing lower AR protein production and androgen signaling.  In a population based study we 
investigated AR CAG repeat length (CAG)nand its association with body fat parameters in Afro-
Caribbean men. 
Design and Subjects: Cross-sectional analysis of 2584 Afro-Caribbean men residing on the 
island of Tobago. 
Measurements: Body mass index (BMI), waist circumference, dual energy x-ray absorptiometry 
(DEXA), AR CAG repeat length genotype. 
Results: Mean age was 59 years. AR CAG repeats lengths ranged from 9 to 33 with a median of 
19. Standardized univariate regression analyses revealed no significant associations between the 
number of CAG repeatsandpercent total body fat ?L\*=$%>.# -%# 7.0*.%/# /+/$2# 4+&5# ,$/# 7.0# CFC#
standard deviation change in  AR CAG repeats), (#=-0.052, P =0.690), BMI (#=-0.184, P =0.085), 
waist circumference (#=-0.236, P =0.352) and weight (#=-0.647, P =0.068). 
Conclusion:LongerAR CAG repeat length was not associated with higher body fat 
measurements. 
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5.2 INTRODUCTION 
Obesity is a major health problem and public health concern361.  Data suggest that genetics in 
conjunction with environmental factors may play a pivotal role in the development of obesity.  
Obesity is associated with a plethora of diseases and increases in risk with increasing age362.  
Obesity phenotypes in individuals appear to be dimorphic.  Men seem to develop an android 
shape (distribution of fat around the abdomen) whereas women distribute fat mainly around the 
hips (gluteofemoral regions) 362, 363.  
Exogenous and endogenous testosterone can affect body composition57. Testosterone is 
important in regulating adiposity, insulin resistance and type II diabetes.  Men with type II 
diabetes have lower testosterone (TT) and sex hormone binding globulin (SHBG) compared to 
normal men364.  Furthermore, lower than normal testosterone levels seem to determine an 
individual’s future risk of developing the metabolic syndrome and type 2 diabetes63, 365, 366.  
Studies have consistently demonstrated that low levels of testosterone and sex hormone-binding 
globulin (SHBG) in men are associated with type 2 diabetes, visceral adiposity, and insulin 
resistance365, 366.Singh et al, delineated that androgens affect the fat cells ability to store lipids by 
interrupting or blocking signal transduction pathways that are important in adipocyte function 
367.  The actions of androgen in developing obesity are thought to be mediated by the androgen 
receptor (AR)368. 
The androgen receptor is important for the regulation of androgen in men. 
Dysfunctional receptors may cause variations in body composition362.  The AR gene is located 
on the X-chromosome (Xq11.2-12), highly polymorphic, and comprised of 8 exons362.  Most 
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studies have focused on two polymorphic trinucleotide repeats (microsatellite) CAG2
5.3 MATERIALS AND METHODS 
coding 
forpolyglutamine and GGN ((GGT)3(GGG)(GGT)2(GGC)n)  coding for glycine351, 362.  CAG 
repeats range between 8-35 369 with an average of 20-23 repeats370.  In vitro studies have 
demonstrated that CAG length is inversely associated with AR transactivation (increased rate of 
gene expression triggered by biological processes) 371.  Longer CAG repeats are associated with 
lower transcriptional activity, Kennedy’s disease, androgen insensitivity and infertility151.  
Polymorphisms of the AR gene are associated with prostate cancer, metabolic, and 
cardiovascular diseases370 and these polymorphic repeats (CAG) can cause variations in serum 
hormone levels leading to hormone-dependent diseases62, 372.   
Studies have also shown that the frequency of the AR gene CAG repeats varies 
amongst different racial and ethnic groups151.  In a population-based study of Afro-Caribbean 
men we investigated the association of AR CAG repeat lengths on body composition parameters.  
We hypothesize that men with longer AR CAG repeats will have more total body fat mass when 
expressed as percent total body mass.  
During 1997 through September 2007, the Tobago Prostate Study recruited 40-79 year old men 
by public service announcements, flyers, local health care workers, and word of mouth to 
participate in a study assessing prostate cancer screening. Men were excluded if they were found 
to be non-ambulatory, terminally ill or cognitively impaired.  All participants signed a written 
                                                 
2 http://www.androgendb.mcgill.ca/ 
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informed consent approved by the Institutional Review Boards of the University of Pittsburgh 
and the Tobago Division of Health and Social Services. 
The Tobago Prostate cohort enrolled 3837 Afro-Caribbean men.  Demographic and 
cancer information were provided by standardized baseline questionnaires. To facilitate genetic 
studies a more detailed staff-administered Health History questionnaire (HH) was used to record 
information on newly recruited or follow-up men beginning January 2004. Our study population 
consisted of 3452 (90.0% of 3837) race-eligible Afro-Caribbean men with ECJ,0+ -Caribbean 
grandparents. 
Procedures consisted of body composition tests (DEXA), and genetic testing.  DEXA 
measurements were obtained on 2850 (82.6%) and health history questionnaires on 2259 
(65.4%) of 3452 race eligible men, and AR CAG genotyping information on 2816 (81.6) of 3452 
race eligible men (2126 with health history information and 690 with no health history 
information).  Two hundred and thirty two (232) individuals were excluded because they did not 
provide any health history (HH) or DEXA information.  Participants with DEXA were pulled 
from both baseline (566 or 22.9%) and follow-up (1902 or 77.1%).  Our final sample size for this 
study was 2584 (Figure 5-1). 
5.3.1 Outcome measurements 
Key outcome variables from the Health History Questionnaire included: height (measured with 
shoes to the nearest 0.1 cm on a wall mounted stadiometer), weight (measured to the nearest 0.1 
kg on a beam balance), body mass index (BMI, calculated as weight in kg divided by height in 
meters-squared), waist circumference (measured in cm at the umbilicus with an inelastic tape 
measure).  Percent total body fatwas ascertained on a Hologic QDR 4500W DEXA operated in 
array beam mode and analyzed by QDR software version 8.26a (Hologic Inc. Bedford, MA).   
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5.3.2 Genotyping 
High molecular weight genomic DNA was isolated from peripheral blood samples using the 
salting out procedure.  To determine the AR CAG repeat length, we constructed a set of 
fluorescent dye labeled oligonucleotideprimersthat flanked the CAG repeat region in exon 1: 
Forward Primer = TET dye-5'-ACCGAGGAGCTTTCCAGAAT-3'; Reverse Primer = 5'-
AGAACCATCCTCACCCTGCT-3'. The DNA was amplified by polymerase chain reaction 
(PCR) to produce fragments which varied in length by the number of CAG repeats. PCR 
consisted of an initial 4-minute denaturation at 95*C, followed by 37 cycles of denaturation 
(95*C, 60 seconds), annealing (58*C, 30 seconds), and elongation (72*C, 60 seconds), and a final 
elongation step (72*C, 10 minutes).  Amplified samples were analyzed by automated high-
throughput scanning fluorescent detectors that have the ability to detect and separate the TET 
dye. To determine the exact number of CAGs for each fragment length, we subsequently 
sequenced a series of PCR products of varying length using standard Sanger sequencing. PCR 
clean up was performed using Exo-SAP according to manufacturer instructions. Sequencing 
buffer and a 1:4 dilution of BigDye 3.1 were added and thermocycling performed according to 
manufacturer recommendations. Removal of unincorporated sequencing reagents was performed 
using CleanSeq magnetic beads according to manufacturer instructions (Beckman Coulter, Inc; 
Brea, CA).  Sanger sequencing was completed using an Applied Biosystems3730xl DNA 
Analyzer 
5.3.3 Statistical analyses 
Statistical analyses were carried out using (SAS 9.2; SAS Institute Inc., Cary NC).  All 
continuous descriptive data are expressed as mean±S.D. To determine the association with 
androgen receptor CAG repeat length correlations were assessed and expressed as Spearman’s 
Rank Correlation coefficient with the associated P-value.  AR CAG data was standardized using 
the formula (CAG repeats-mean of CAG)/Standard Deviation of CAG before univariate linear 
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regression.  Univariate linear regression techniques were used to assess the independent 
association between standardized AR CAG and body fat parameters. Results are expressed using 
the regression coeff-*-.%/# ?L3# ?4./$# *+.,,-*-.%/8# $0.# .e70.88.&# -%# /.068# +,# *=$%>.# -%# /=.#
independent variable per one standard deviation unit change in the number of CAG repeats) and 
the associated P-value.  Stratified regression analyses were also performed according to BMI and 
age categories using linear regression. 
5.4 RESULTS 
Table 5-1 summarizes characteristics by (mean±SD) of the study population according to long 
vs. short repeats.  In Table 5-1 we see that the means were the same in the long and short AR 
CAG repeat groups except for BMI which showed that the means were statistically different 
(p=0.03).  These variables used in this analysis were pulled from the Health History 
Questionnaire. The number of AR CAG repeats ranged from 9-33 with a median of 19 (Figure 
5-2).  The average age of participants was 59 years.  To determine the frequency of long versus 
short repeats, AR CAG repeat length was split into low (f::3 and high groups (>22) according to 
Campbell et al373.Approximately 81.4% or 2103 of (2584) had short repeats and 18.6% or 481 
participants had long repeats (Table 5-2).Table 5-3 describes potential confounders (Health 
History Questionnaire) by long and short repeats. The proportion of men with heart attack 
(dichotomous variable) was significantly different (P=0.0302) according to long versus short 
repeats.   
In our analysis multiple body fat parameters were explored including: percent trunk fat, 
percent limb fat, percent arm fat, and percent leg fat. Spearman-Rank order correlation analysis 
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revealed no significant association between ARgene CAG repeat polymorphism as a continuous 
variable and body fat parameters (Table 5-4). Univariate regression analyses revealed no 
significant associations between AR gene CAG repeat length as standardized continuous variable 
and body fat parameters, percent total body fat (#=-0.052, P =0.690), BMI (#=-0.184, P =0.085), 
waist circumference (#=-0.236, P =0.352) and weight (#=-0.647, P =0.068) (Table 5-5).  The 
negative #-coefficient indicates that men with shorter CAG repeats had higher body fat 
measurements. In addition, comparison of included (2584) and excluded (232) participants 
revealed that the median number of AR CAG repeats was the same for both groups (Table 5-6).  
Table 5-8 presents stratified regression analysis by age category. This analysisdid not 
detect, in any age group, a statistically significant associationbetweenthe number 
ofARCAGrepeatsandpercent total body fat.  Table 5-9 presents stratified analysis by BMI 
category. Likewise, this analysis did not detect, in any BMI category,a statistically significant 
association between the number of AR CAG repeats and percent total body fat.  Moreover, the 
negative association observed between different measures of body fat and AR CAG repeats 
shown in Table 5-10 was not significant even after adjusting for age for all body fat parameters 
except BMI which was statistically significant with a P=0.04 (Table 5-10).  In addition, Table5-7 
also shows a significant negative association unadjusted for age (P=0.04).  Therefore regardless 
of how the analyses were performed, age adjusted or not, the associations observed in this cohort 
were not altered. We also do recognize that different sample sizes were used in the analyses 
presented so far and that caution should be used in making inferences.  Hence, in an effort to 
show a more complete analysis various non-missing sample sizes were used in analyses shown in 
Table 5-11.  Even in these analyses, a persistent non-significant negative association was 
observed between AR CAG and percent total body fat.  On the other hand BMI continued to 
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show a statistically significant negative association with AR CAG length.  In this population 
having shorter AR CAG means that men may be fatter opposite what was originally 
hypothesized. 
5.5 DISCUSSION 
Our study revealed thatlonger AR CAG was not associated with higher body fat parameters.  
Instead our study revealed that men with shorter AR CAG had higher measures of body fat.  
Studies elucidating an association betweenAR-CAG repeat length and body composition 
have produced inconsistent results.  For instance, Lapauw et al374, did not find an association 
between AR CAG repeat length and body composition parameters.  This non-significant finding 
in Belgium men persisted even after the adjustment of potential confounders (age, weight, total 
testosterone and sex hormone binding globulin (SHBG)). However, Campbell et al373 reported an 
association between AR CAG repeats and body composition parameters contrary to findings 
reported in the aforementioned study.  In Campbell’s study amongst the Ariaal men of northern 
Kenya AR CAG repeats were positive predictors of height (#=0.420, P<0.05), fat free mass 
(#=0.383, P<0.05), percent body fat (#=0.329, P<0.05), waist circumference (#=0.385, P<0.05), 
and suprailliacskinfold (#=0.760, P<0.001).  Both Campbell et al373 and Lapauw et al374 report a 
regulatory effect of the AR CAG repeats on testosterone and consequently the relationship 
between testosterone (serum testosterone concentration) and body composition (Lapauw et 
al374#=0.12, P<0.1 modeled an interaction between CAG repeat and testosterone).  Possible 
explanations for our results of no association include: Campbell et al373 study consisted of a 
younger cohort of men 20+ compared to our study in which age ranged from 33-91 years. 
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Other explanations for the divergent results observed may be explained by gene-
environment interaction, and differences in study design.  Moreover, it has been postulated that 
AR CAG repeats may function as low penetrance alleles that require the presence of additional 
genetic and environmental factors to cause an increase in disease susceptibility375. It is quite 
possible that AR CAG may be in linkage disequilibrium with other mutations in the AR gene (on 
the X-chromosome) such as (GGN) that are in close proximity at a particular locus or other 
unknown genes370 that may affect body composition in men. Furthermore, obesity is a 
multifactorial disease that may be affected by other hormones, diet and lifestyle that were not 
accounted for in the present study.  
Non-the-less, the results presented in this paper are of interest because based on our 
knowledge there have been relatively few studies evaluating the AR gene in populations of 
African descent with a large sample size. 
5.5.1 Racial differences in CAG repeat length 
The distribution of CAG repeats has been reported to differ amongst different racial and ethnic 
groups.  African Americans have been found to have shorter CAG repeats compared to 
Caucasians (19.8 vs. 21.9)151. Sartor et al376 reported almost twice as many black men had 
shorter CAG repeats (<20 vs. >20) compared to non-Hispanic white men (56.92% vs. 28.46%) 
with mean repeats of 19.0 vs. 21.0.  The findings of shorter CAG repeats in previous studies are 
inline with the findings from our study of a mean of 19.7 and a median of 19.  
Limitations of our study include: our study was based on a single time point DEXA 
measurements where longitudinal data might have provided additional information. 
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Figure 5-1: Sample selection for paper 2. 
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Figure 5-2: Distribution of AR CAG repeat length. 
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Table 5-1: Body composition measures (mean±standard deviations) according to AR CAG genotype. 
    AR CAG repeat length  
                   
    f::#     >22   
Body composition measure n mean ± SD  n mean ± SD 
P-
value 
[1] 
Age (years) 1733 58.98 ± 10.49  393 58.94 ± 10.25 0.95 
Age at 2nd DEXA (years) 2013 59.20 ± 10.94  455 59.28 ± 10.63 0.78 
Weight (kg) 1726 84.85 ± 16.71  392 83.15 ± 15.03 0.09 
Body mass index (kg/m2) 1724 27.68 ± 5.04  392 27.10 ± 4.48 0.03 
Waist circumference (cm) 1717 93.40 ± 11.77  393 92.66 ± 11.40 0.23 
Percent total body fat (%) 2013 21.06 ± 6.42   455 20.71 ± 6.67 0.31 
1. Wilcoxon-Mann-Whitney test           
Data presented as mean±S.D 
Data restricted to individuals with non-missingAR CAG repeat length genotype and EC#Jfro-Caribbean grandparents 
Percent total body fat calculated as total fat 100*mass/total body mass. 
 
 
 
 
 
 
Table 5-2:Proportion of men with long vs. short AR CAG repeats (N=2584). 
AR CAG 
Repeats  Men (N)  Men (%) 
<=22 2103 81.4 
>22 481 18.6 
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Table 5-3: Potential confounders. 
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Table 5-4: Spearman rank correlations between AR CAG repeats and body composition measures. 
 Weight 
Waist 
circum-
ference 
Body mass 
index 
Total body 
fat 
Trunk 
body fat 
Arm body 
fat 
Leg body 
fat 
Limb body 
fat 
CAG repeat length -0.04 -0.02 -0.04 -0.01 -0.02 0.00 0.00 0.00 
Weight  0.83* 0.89* 0.59* 0.60* 0.58* 0.51* 0.55* 
Waist 
circumference   0.84* 0.76* 0.76* 0.73* 0.65* 0.70* 
Body mass index    0.68* 0.68* 0.68* 0.58* 0.63* 
Total body fat     0.97* 0.92* 0.92* 0.96* 
Trunk body fat      0.86* 0.81* 0.86* 
Arm body fat       0.83* 0.92* 
Leg body fat               0.98* 
Entries correlation coefficients. *P<0.001. 
Data based on restrictions to individuals with CAG repeat length genotyping information, and EC#$,0+ -Caribbean grandparents. 
The number of observations used to estimate individual correlations range between 1998 to 2468 
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Table 5-5: Results from standardized univariate linear regression models (n=2584). 
Attribute ! SE t-value P-value 
Age (years) 0.155 0.219 0.71 0.48 
Body weight (kg) -0.647 0.354 -1.830 0.068 
Waist circumference (cm) -0.236 0.253 -0.930 0.352 
Body mass index (kg/m2) -0.184 0.107 -1.720 0.085 
Percent total body fat (%) -0.052 0.130 -0.400 0.690 
Percent trunk fat (%) -0.109 0.141 -0.780 0.438 
Percent arm fat (%) 0.003 0.152 0.020 0.984 
Percent leg fat (%) 0.010 0.124 0.080 0.935 
Percent limb fat (%) 0.005 0.128 0.040 0.969 
Entries are standardized linear regression coefficients  
Data presented are participants who are race eligible (>=3 Afro-Caribbean grandparents) 
with AR CAG genotyping 
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Table 5-6:A comparison of ARCAGlength between excludedmen (men excluded from analysis because of 
missing DEXA and missing HH questionnaire) and included men (men included in analysis of association 
between AR CAG and body composition). 
Study N       Q25 Median       Q75 P-value 
Excluded 232 18 19 22 0.45 
Included 2584 17 19 22  
Q25, 25th Percentile; Q75, 75th percentile 
 
 
 
Table 5-7: Unadjusted AR CAG repeat length category (<=22 vs. >22 repeats) associations with age, weight, 
body mass index (BMI), percent total body fat, percent trunk fat, percent arm fat, percent leg fat, percent 
limb fat (n=2584). 
Attribute ! SD t-value P-value 
Age(years) 0.07 0.56 0.13 0.90 
Weight (kg) -1.70 0.92 -1.85 0.06 
Average standing height (cm) 0.06 0.38 0.17 0.87 
Waist circumference (cm) -0.73 0.65 -1.12 0.26 
Body Mass Index (kg/m2) -0.58 0.28 -2.10 0.04 
Percent trunk fat (%) -0.27 0.36 -0.73 0.46 
Percent arm fat (%) -0.41 0.39 -1.04 0.30 
Percent leg fat (%) -0.44 0.32 -1.39 0.16 
Percent limb fat (%) -0.44 0.33 -1.35 0.18 
Percent total body fat (%) -0.35 0.34 -1.04 0.30 
Entries linear regression coefficients 
Data presented are participants who are race eligible (>=3 Afro-Caribbean 
grandparents) with AR CAG genotyping and DEXA 
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Table 5-8: Association between AR CAG repeat and percent total body fat, by age. 
Age category (years) N !=+>?@ABCD%2090&15 P-Value 
33-50 652 -0.08 0.32 
51-57 570 0.09 0.29 
58-66 572 -0.04 0.59 
67-92 674 -0.05 0.55 
Age in years    
%TBF; change in percent total body fat 
CAG repeat; change in CAG repeat length 
Estimated regression coefficients  
 
 
 
 
Table 5-9: Association between AR CAG repeat and percent total body fat, by BMI category. 
BMI category N !=+>?@C>ABCD%E090&15 P-Value 
Underweight 29 -0.04 0.83 
Normal weight 609 -0.01 0.83 
Overweight or obese 1478 0.04 0.33 
%TBF; change in percent total body fat 
CAG repeat; change in CAG repeat length 
Estimated regression coefficients  
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Table 5-10:Age-adjusted associations between AR CAG repeat length category (<=22 vs. >22 repeats) and 
eight different measures of body composition (n=2584). 
  Dependent variables           
 PcnTBFat Weight Waist circumference Body mass index 
 L P L P L P L P 
CAG repeata 
<=22 vs.>22 -0.36 0.28 -1.71 0.056 -0.73 0.26 -0.58 0.034 
 Dependent variables           
 PcnTarmFat PcnTlimbFat PcnTlegFat PcntTrunkFat 
 L P L P L P L P 
CAG repeata 
<=22 vs.>22 -0.42 0.28 -0.45 0.16 -0.45 0.15 -0.27 0.45 
aAdjusted for age         
BMI, body mass index; PcnTBfat, percent total body fat; PcnTarmFat, percent arm fat; PcnTlimbFat, percent 
limb fat; PcntlegFat, percent leg fat; PcnTtrunkFat, percent trunk fat;  
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Table 5-11: AR CAG repeat length associations with age, BMI, and percent total body fat, in study groups 
defined differently with respect to the availability of BMI and percent total body fat information. 
Table 5-11a: TBFat% not missing AND BMI not missing at the visit with the non-missing DEXA, n=2330. 
  
Rank order 
correlation with 
AR CAG repeat 
number  
Average difference in the dependent 
variable, comparing men with long 
(23-33 repeats) vs. short (9-22 
repeats) AR CAG 
Parameters n r p-value   L S.E. t-value p-value 
Age at DEXA visit (years) 2330 0.02 0.40  0.09 0.58 0.16 0.87 
BMI at DEXA visit (kg/m2) 2330 -0.05 0.02  -0.54 0.25 -2.14 0.03 
TBFat% 2330 -0.01 0.73   -0.37 0.35 -1.07 0.29 
Age, BMI, and TBFat% pulled from Visit 1 and 3 in 435 and 1895, respectively 
TBF%; percent total body fat 
Table 5-11b: TBFat% not missing, n=2468. 
  
Rank order 
correlation with AR 
CAG repeat 
number  
Average difference in the dependent 
variable, comparing men with long 
(23-33 repeats) vs. short (9-22 
repeats) AR CAG 
Parameters n r p-value   L S.E. t-value p-value 
Age at DEXA visit (years) 2468 0.01 0.52  0.07 0.56 0.13 0.90 
BMI at DEXA visit (kg/m2) 2330 -0.05 0.02  -0.54 0.25 -2.14 0.03 
TBFat% 2468 -0.01 0.68  -0.35 0.34 -1.04 0.30 
Age, BMI, and TBFat% pulled from Visit 1 and 3 in 566 and 1902, respectively 
TBF%; percent total body fat 
Table 5-11c: BMI not missing, n=2466. 
  
Rank order 
correlation with AR 
CAG repeat 
number  
Average difference in the dependent 
variable, comparing men with long 
(23-33 repeats) vs. short (9-22 
repeats) AR CAG 
Parameters  n r p-value   L S.E. t-value p-value 
Age at BMI visit (years) 2466 0.02 0.37  -0.04 0.55 -0.08 0.94 
BMI (kg/m2) 2466 -0.05 0.01  -0.62 0.25 -2.44 0.01 
TBFat% 2355 -0.01 0.63  -0.43 0.34 -1.25 0.21 
BMI pulled from Visit 3, if not missing, from Visit 1, otherwise 
Age and BMI pulled from Visit 1 and 3 in 350 and 2116, respectively 
TBFat% (available in n=2355) pulled from Visit 1 and 3 in 455 and 1900, respectively 
TBF%; percent total body fat 
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Table 5-11d: TBFat% not missing OR BMI not missing, n=2585. 
  
Rank order 
correlation with 
AR CAG repeat 
number  
Average difference in the dependent 
variable, comparing men with long 
(23-33 repeats) vs. short (9-22 
repeats) AR CAG 
Parameters  n r p-value   L S.E. t-value p-value 
Age at DEXA visit (years) 2468 0.01 0.52  0.07 0.56 0.13 0.90 
BMI at Visit 3 (kg/m2) 2116 -0.04 0.08  -0.58 0.28 -2.10 0.04 
TBFat% 2468 -0.01 0.68  -0.35 0.34 -1.04 0.30 
N=2468 with non-missing TBFat% and 2116 with non-missing Visit 3 BMI. 
Age and TBFat% pulled from Visit 1 and 3 in 566 and 1902, respectively 
TBF%; percent total body fat 
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6.1 ABSTRACT 
Objective:  A common treatment for prostate cancer is androgen deprivation therapy (ADT). 
ADT affects the body by lowering the concentrations of androgen.  This can have adverse side 
effects of which changes in body composition is a major concern.  These changes may influence 
risk for other chronic diseases 
Design and Subjects: Case-control Study analysis of 1691 Afro-Caribbean men residing in 
Tobago and participating in a prostate cancer screening study.  Controls included participants 
without a history of prostate cancer and individuals with prostate cancer unexposed to ADT. 
Measurements:  Body mass index (BMI), waist circumference, total fat estimated by dual 
energy x-ray absorptiometry (DEXA). 
Results: Percent total body fat increased over time (mean ±S.E.) (0.57±0.08) compared in men 
with prostate cancer treated with ADT compared to men with prostate cancer unexposed to ADT 
(0.29±0.07) with a p-value for change (0.28±0.11, P=0.0111).  The change in men with prostate 
cancer unexposed to ADT did not differ from controls with prostate cancer  
Conclusion:  Men with prostate cancer exposed to ADT had greater gains in percent total body 
fat over time compared to men unexposed to ADT. 
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6.2 INTRODUCTION 
Prostate cancer is known as one of the most common malignancies affecting black men in the 
United States and other countries around the world351.  There are considerable variations in 
prostate cancer incidence across racial/ethnic groups with people of African descent having the 
highest rates, whites having an intermediate rate and Asians the lowest 53, 55, 351.  Even though 
this disparity remains to be clearly elucidated, possible explanations for the overt population 
differences include androgen levels, and dietary factors 351, 377.   
The production of androgen is regulated by the hypothalamic–pituitary-gonadal axis.  
Gonadotropin releasing hormone is secreted by the hypothalamus stimulating the pituitary gland 
to secrete luteinizing hormone, which acts on the Leydig cells of the testis to produce androgen.  
Testosterone is the main androgen circulating in males.  However, Dihydrotestosterone (DHT) is 
considered the most potent androgen and the main androgen found in tissue351. Testosterone 
moves from the blood into the prostate where it binds to the Androgen receptor (AR)53.  
Testosterone is also converted to DHT by the enzyme 5' -reductase types II which is encoded by 
the SRD5A2 gene.DHT binds to the Androgen receptor in addition to its co-regulators 
(AIB1/SRC3) and co-repressors (DAX1 and SHP) (the androgen receptor has a higher affinity 
for DHT) in the cytoplasm and is then translocated into the nucleus where transcription begins 
378.Androgens are steroid hormones that influence the development of male secondary sex 
characteristics.  In men androgen are developed in the testes and the adrenal glands and are 
metabolized in the prostate and skin351.Testosterone and DHT exact their androgenic effects 
through the androgen receptor351. 
There is evidence suggesting that serum levels of testosterone are associated with the 
development of prostate cancer.  A high level of serum testosterone is associated with an 
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increased risk of low-grade prostate tumors and a decreased risk of low-grade prostate cancer.  
Whilst low levels of serum testosterone is associated with an increased risk of high grade 
prostate cancer and reduced risk of low grade prostate cancer378.  
A common treatment of prostate cancer is androgen deprivation therapy (ADT).  ADT 
involves the suppression of gonadal androgen in the body.  This can be accomplished through a 
variety of ways some of which are orchiectomy, and gonadotropin-releasing hormone.  ADT has 
numerous side effects such as sexual side effects, hot flashes, gynecomastia, changes in body 
composition, metabolism, osteoporosis, the cardiovascular system, cognition problems and an 
overall decline in one’s quality of life 379.  This paper investigates the association between ADT 
treatment for prostate cancer and rate of change in percent total body fat in Afro-Caribbean men 
from Tobago. 
6.3 MATERIALS AND METHODS 
6.3.1 Study sample 
From 1997 until September 2007, the Tobago Prostate Study recruited 40 to 79 year old men to a 
population-based prostate cancer screening study.  The men were recruited by public service 
announcements, flyers, local health care workers, and by word of mouth to participate in a study 
evaluating prostate cancer screening.  Men were excluded from the study if they were 
determined to be non-ambulatory, terminally ill, or cognitively impaired.  All eligible 
participants signed a written informed consent approved by the institutional review boards of the 
University of Pittsburgh and the Tobago Division of Health and Social Services.   
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The Tobago Prostate study enrolled 3837 Afro-Caribbean men (Five hundred and thirty 
one men were excluded because 485 were new enrollees and did not have a baseline DEXA and 
46 were less than 40 years of age).  Demographic and cancer information was provided by staff-
administered standardized baseline questionnaire and a more detailed follow-up questionnaire 
(Health History Questionnaire).  The Health History questionnaire was used to record 
information on newly recruited and follow-up men beginning January 2004.  Our study consisted 
of 3452 (90% 0f 3837) race eligible Afro-Caribbean men with EC#J,0+-Caribbean grandparents.   
Procedures consisted of body composition measurements (DEXA).  Dexa measurements 
were obtained on 2850 (82.6%) and health history (HH) questionnaires on 2259 (65.4%) of 3452 
race eligible men.  Our final sample size was 1691 (Figure 6-1).  Men with prostate cancer were 
categorized as unexposed to ADT, and ADT exposed based on questions from questionnaires.  
ADT constituted either treatment with gonadotropin releasing hormone (GnRH) agonists, 
luteinizing releasing hormone (LHRH), anti-androgens, orchiectomy, or any combination of the 
aforementioned. 
6.3.2 Outcome measurements 
Important outcome variables included height (measured with shoes to the nearest 0.1 cm on a 
wall mounted stadiometer), weight (measured to the nearest 0.1 kg on a beam balance), body 
mass index (BMI- calculated as weight in kg divided by height in meters-squared), waist 
circumference (measured in centimeters at the umbilicus with an inelastic tape measure).  These 
key anthropometric measures were ascertained from the HH questionnaire.  Percent total body 
fat was ascertained on a hologic QDR4500W DEXA operated in array beam mode and analyzed 
by QDR software version 8.26a (Hologic Inc. Bedford, MA).  Prostate specific antigen test prior 
to year 2000 was the Abbot AxSYM PSA assay (Abbott Laboratories, Abbott Park, IL, USA) 
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and after 2000 the PSA assay was the Advia (Siemen’s) Centaur (Siemens Healthcare Diagnostic 
Advia Centaur, Deerfield, IL). 
6.3.3 Statistical Analyses 
All statistical analyses were performed using SAS® software, version 9.2 (SAS Institute, Inc., 
Cary, NC, USA).  Descriptive statistics were used to characterize the six groups in the study 
sample.  Three hundred individuals and two were determined to have prostate cancer and these 
individuals were placed in particular groups depending on when they were diagnosed with 
prostate cancer.  143 individuals were diagnosed with prostate cancer before initial DEXA (80 
unexposed to ADT and 60 ADT exposed), 98 were diagnosed with prostate cancer between 
initial and repeat DEXA (59 unexposed to ADT and 39 ADT exposed), and 61 were diagnosed 
with prostate cancer after repeat DEXA (59 unexposed to ADT, and 2 ADT exposed).  Analysis 
of variance (one-way-ANOVA) was used to compare the mean difference among the groups.  
Adjusted comparisons controlled for baseline percent body fat measurements, ageand PSA as 
potential confounders.   
6.4 RESULTS 
Of the individuals enrolled in the study, 143 individuals were diagnosed with prostate cancer 
before initial DEXA (80 unexposed to ADT and 60 ADT exposed), 98 were diagnosed with 
prostate cancer between initial and repeat DEXA (59 unexposed to ADT and 39 ADT exposed), 
and 61 were diagnosed with prostate cancer after repeat DEXA (59 unexposed to ADT, and 2 
ADT exposed).  The 2 ADT exposed individuals were excluded from the study because this 
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group was extremely small to use in making any reliable conclusions. Our control group 
consisted of, 1391 individuals without a history of prostate cancer and unexposed to ADT (21 
individuals indicated that they were ADT exposed on questionnaires but they had no history of 
prostate cancer; these individuals were excluded (Figure 6-1).  One person was also excluded 
from the final analysis because they did not have all the relevant repeat DEXA measurements).  
The majority of the study samples were Afro-Caribbean andparticipants were more likely to be 
married and have at least a primary school level education.  Table 6-1 shows the mean and 
standard deviation for a number of clinical characteristics.  Men had significantly different age 
(P=0.0001), percent total body fat (P=0.0076) and Prostate specific antigen (P=0.0001) across 
groups.  Mean body mass index was not significantly different across groups (P=0.6691). 
Table 6-2 shows the mean change in percent total body fat in men according to prostate 
cancer status and ADT exposure.  In men exposed and unexposed to ADT who had their prostate 
cancer diagnosed before the 1st DEXA had significant mean difference in percent total body fat 
unadjusted (P=0.0056), adjusted for age (P=0.0036) and adjusted for age and 1st DEXA percent 
total body fat (P=0.0021).Similar findings were also observed in men exposed and unexposed to 
ADT with prostate cancer diagnosed between the 1st and 2nd DEXA scans; unadjusted 
(P=0.0041), adjusted for age (P=0.0032) and adjusted for age and 1st DEXA percent total body 
fat (P=0.0021).  Men with prostate cancer diagnosed after repeat (2nd) DEXA and unexposed to 
ADT had similar mean difference in percent total body fat (prostate cancer diagnosed after 2nd 
DEXA (0.82±0.31), compared to men without prostate cancer (0.80±0.07).  Finally Table 6-3 
shows the rate of change of percent body fat in the six groups.  Overall table 4 indicates that the 
rate of change of percent total body fat was greater in persons exposed to ADT than in persons 
unexposed the ADT.  In the prostate cancer diagnosed after 2nd DEXA and Healthy controls the 
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mean rate of change of percent total body fat was similar 0.17±0.09 and 0.18±0.02.  The 
difference in the two mean rate of change of percent total body fat 0±0.09, p=0.9626. 
Table 6-4 shows the median years between initial and repeat DEXA, which was 
approximately 4.5 years.Table6-5 shows the frequency of the type of androgen deprivation 
therapy used.  Antiandrogen, GnrH, and LHRH was the treatment of choice in this cohort. 
Antiandrogen, GnrH, and LHRH was used in 74.6% (47) in prostate cancer diagnosed after 1st 
DEXA and 76.9% (30) in the group prostate cancer diagnosed between the 1st and 2nd DEXA.  
Nineteen percent (12) persons had orchiectomy only, in the group prostate cancer diagnosed after 
1st DEXA and 12.8% (5) persons had orchiectomy in the group prostate cancer diagnosed 
between 1st and 2nd DEXA.  Four (6.3% and 10.3% respectively) had combined treatments in 
both groups. 
6.5 DISCUSSION 
Androgen suppression or androgen ablation or androgen deprivation is chemical treatment to 
suppress or block the production or action of the male sex hormone to treat prostate cancer in 
men.  Two common methods by which this can be done is by removing the testicles or by taking 
anti-androgens 380.  There are several different types of anti-androgen drugs available.  In our 
study evaluating the effect of ADT on percent total body fat we determined that percent total 
body fat increased in men with prostate cancer exposed to ADT.  In comparison men without 
prostate cancer and men with prostate cancer who did not initiate ADT therapy had much lower 
increases in percent body fat.   
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Androgens are considered important determinants of body composition in men.  ADT has 
been shown to increase serum triglycerides and cholesterol380. A reduction in muscle mass in 
men leads to reduced strength and increased risk of falls and fractures (sarcopenia)14.  The 
replacement of androgen in the body reverses the effects of androgen deprivation28.  In men with 
prostate cancer the use of androgen antagonist affects the body by reducing physical function380. 
Our results support an increase in percent total body fat measured by DEXA following 
ADT administration in Afro-Caribbean men with prostate cancer.However, there were several 
limitations with our study.  First we were unable to determine the duration of ADT treatment.  It 
is possible that men who had a longer duration of ADT gained more fat.  Hence, our study even 
though we found an increase in percent body fat may have underestimated the response.  We also 
encountered possible information bias.  There were 21 individuals who did not have prostate 
cancer but reported that they were taking ADT.  ADT exposure variable was determined from 
self-report and was not independently verified.  These individuals were of course excluded from 
the study.  There was also the issue of channeling bias; beyond PSA clinical indications for ADT 
treatment may have confounded observed associations between ADT and changes in percent 
total body fat.  Moreover, some individuals with prostate cancer were prescribed ADT while 
others were not.  One can only speculate about possible reasons why some individuals received 
ADT treatment and others did not such as the cases were more advanced or had metastasized, or 
maybe it was not affordable. Another limitation was selection bias; the requirement that 
participants have a second DEXA may have excluded some men according to ADT exposure and 
outcome.  Finally we had small sample sizes for the various groups. 
Nonetheless, our study had important strengths.  It prospectively observed body 
composition changes following ADT administration.  Two different control groups were used for 
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comparison (healthy controls and prostate cancer individuals unexposed to ADT).  Finally we 
used dual-energy absorptiometry machine to determine percent total body fat measurements.   
In summary, the results of our study should be interpreted with caution because of the 
small sample size.  Non-the-less, in men with prostate cancer percent total body fat increased 
over time, on average, more so in men exposed than in men unexposed to ADT. 
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Figure 6-1: Sample selection for Paper 3. 
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Table 6-1: Baseline body composition characteristics (mean ±S.D.). 
 
 
 
 
Abbreviations: TBF (%); Percent total body fat; ADT; Androgen deprivation therapy 
PSA; Prostate specific antigen 
Age used in this table was the age at 1st DEXA 
Parameter 
Prostate cancer before 1st 
DEXA  
Prostate cancer diagnosis 
between1st and 2nd DEXA  
Prostate 
cancer after 
2nd DEXA 
No Prostate 
cancer 
P-Value 
(across 
groups) 
 ADT (n=63) 
No ADT 
(n=80)  ADT (n=39) 
No ADT 
(n=59)  
No ADT 
(n=59) 
No ADT 
(n=1391)  
Age (years) 67.9±6.9 63.58±8.7  64.5±6.97 61.76±9.0  58.3±7.85 53.71±9.9  0.0001 
BMI (kg/m2) 26.89±4.3 28.2±4.1  27.3±4.15 27.2±3.03  27.42±4.02 27.57±4.2  0.6691 
TBF (%) 22.75±5.7 21.7±6.8  21.26±5.76 20.52±5.1  20.01±6.3 20.17±6.2  0.0076 
PSA (ng/ml) 23.64±34.6 9.69±18.35  10.14±10.52 15.54±45.34  8.92±24.61 2.21±10.69  0.0001 
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Table 6-2:BF&'G0%/'%902,0'1%1-1&4%6-(7%.&1%=#>?@&1+5%67%92-:1&10%,&',02%:1&1;:%&'(%&'(2-G0'%(092/3&1/-'%0H9-:;20. 
             
 Androgen deprivation treatment     
 Yes  No     
  !@AB$/)   !@AB$/)  
!#
meanTBFat%  
Categories N Mean S.E.  N Mean S.E.  Delta S.E. 
p-
value 
Prostate cancer diagnosed before 1st DEXA scan            
Unadjusted 63 2.56 0.43  80 1.25 0.39  1.30 0.47 0.0056 
Age-adjusted 63 2.50 0.44  80 1.30 0.39  1.37 0.47 0.0036 
Age and 1st DEXA scan TBFat%-adjusted 63 2.85 0.36  80 1.43 0.31  1.42 0.46 0.0021 
Age, psa, and 1st DEXA scan TBFat%-adjusted 63 2.75 0.36  80 1.40 0.31  1.35 0.46 0.0038 
            
Prostate cancer diagnosed between 1st and 2nd DEXA scans            
Unadjusted 39 3.16 0.45  59 1.50 0.37  1.66 0.58 0.0041 
Age-adjusted 39 3.08 0.45  59 1.55 0.37  1.70 0.58 0.0032 
Age and 1st DEXA scan TBFat%-adjusted 39 3.29 0.44  59 1.55 0.36  1.74 0.56 0.0021 
Age, psa, and 1st DEXA scan TBFat%-adjusted 39 3.28 0.44  59 1.49 0.36  1.78 0.57 0.0017 
            
Prostate cancer diagnosed after 2nd DEXA scan            
Unadjusted     59 0.82 0.31     
            
No prostate cancer            
Unadjusted     1391 0.80 0.07     
Legend:            
!@AB$/)#\#:%&#IXgJ#8*$%#@AB$/)#– 1st DEXA scan TBFat%            
Delta = mean TBFat% in the group that received androgen deprevation treatment – mean TBFat% in the group that did not receive androgen deprivation 
Treatment 
PSA; prostate specific antigen 
Values for comparison groups, no prostate cancer and prostate cancer diagnosed after 2ndIXgJ#?!6.$%@AB)M#TFTS(C3M##?KFXFM#TFCRTR]3#$%&#?h-value=0.9672) 
  
  120 
Table 6-3:I0&'%2&10%-.%,F&'G0%-.%902,0'1%1-1&4%6-(7%.&1%=#>?@&1+5%67%92-:1&10%,&',02%&'(%&'(2-G0'%(092/3&1/-'. 
                        
 Androgen deprivation treatment     
 Yes  No     
  
rate of 
!@AB$/)   
rate of 
!@AB$/)  Delta  
Categories N Mean SE   N Mean SE  Mean S.E. 
p-
value 
Prostate cancer diagnosed before 1st DEXA scan                   
Unadjusted 63 0.57 0.08  80 0.29 0.07  0.28 0.11 0.0111 
Age-adjusted 63 0.61 0.09  80 0.31 0.07  0.30 0.11 0.0077 
Age and 1st DEXA scan TBF%-adjusted 63 0.63 0.08  80 0.32 0.07  0.31 0.11 0.0047 
Age, psa and 1st DEXA scan TBF%-adjusted 63 0.61 0.09  80 0.32 0.07  0.29 0.11 0.0084 
                        
Prostate cancer diagnosed between 1st and 2nd DEXA scans                   
Unadjusted 39 0.68 0.11  59 0.33 0.09  0.35 0.14 0.0094 
Age-adjusted 39 0.71 0.11  59 0.35 0.09  0.36 0.14 0.0077 
Age and 1st DEXA scan TBF%-adjusted 39 0.71 0.10  59 0.34 0.08  0.37 0.13 0.0054 
Age, psa and 1st DEXA scan TBF%-adjusted 39 0.70 0.11  59 0.32 0.09  0.38 0.13 0.0047 
                        
Prostate cancer diagnosed after 2nd DEXA scan                   
Unadjusted     59 0.17 0.09     
                     
No prostate cancer            
Unadjusted         1391 0.18 0.02         
Legend:            
0$/.#+,#!@AB$/)#\?#:%&#IXgJ#8*$%#@AB$/)#– 1st DEXA scan TBFat%)/ years between 1st and 2nd DEXA      
I.2/$#\#6.$%#0$/.##!@AB$/)#-%#/=.#>0+97#/=$/#0.*.-1.&#$%&0+>.%#&.70.1$/-+%#/0.$/6.%/#-6.$%##0$/.#!@AB$/)#-%#/=.#>0+97#/=$/#&-&#%+/#0.*.-1.#androgen 
deprivation treatment 
PSA; prostate specific antigen            
Values for comparison groups, no prostate cancer and prostate cancer diagnosed after 2ndIXgJ#?0$/.#+,#!6.$%@AB)M#TFTT3M##?KFXFM#TFT'3#$%&#?h-value=0.9626) 
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Table 6-4:Tobago Prostate Study, subject mean age, median interval between sequential DEXA scans, median interval between prostate cancer 
diagnosis and first DEXA, and median interval between prostate cancer diagnosis and second DEXA, according to prostate cancer status, timing of 
prostate cancer diagnosis with respect to sequential DEXA, and prostate cancer treatment status (ADT vs. no ADT). 
 
 
    
Age Tobago 
entry (years)   
Age at initial 
DEXA 
(years) 
Years between initial and 
repeat DEXA   
Years from diagnosis to 
initial DEXA   
Years from diagnosis to 
repeat DEXA 
Category N Mean  S.D.   Mean  S.D. Median Q25 Q75 Median Q25 Q75 Median Q25 Q75 
No prostate cancer  1391 52.55 9.69   53.71 9.92 4.45 3.95 4.77                 
Prostate cancer before initial 
DEXA, no ADT 
80 62.28 8.62   63.59 8.77 4.50 4.05 4.76   0.71 0.38 1.11   5.25 4.72 5.53 
Prostate cancer before initial 
DEXA, ADT 
63 66.64 6.85   67.89 6.91 4.36 4.08 4.88   0.88 0.42 1.50   5.45 5.07 6.26 
Prostate cancer between initial and 
repeat DEXA, no ADT 
59 60.88 9.15   61.76 9.01 4.65 4.33 5.04   -1.04 -1.78 -0.27   3.73 2.95 4.50 
Prostate cancer between initial and 
repeat DEXA, ADT 
39 57.15 7.69   64.49 6.97 4.56 4.31 4.91   -0.84 -1.89 -0.21   3.37 2.51 4.82 
Prostate cancer after repeat DEXA 59 52.55 9.69   58.31 7.86 4.61 4.24 4.94   -5.62 -6.75 -5.03   -0.76 -2.19 -0.27 
Legend:                  
Q25; 25 percentile; Q75; 75 percentile                 
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Table 6-5:Type of androgen deprivation,in men reporting an ADT exposure. 
Type of androgen deprivation 
Prostate cancer 
before 1st DEXA 
and ADT exposed 
(N=63) 
Prostate cancer 
diagnosis between 
1st and 2nd DEXA 
and ADT exposed 
(N=39) 
 N % N % 
Medical treatment only (anti-androgen or LHRH agonist) 47 74.6 30 76.9 
Surgical treatment (orchiectomy) only 12 19.0 5 12.8 
Medical and surgical treatment 4 6.3 4 10.3 
Legend:     
ADT, androgen deprivation therapy     
LHRH, luteinizing hormone releasing hormone    
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